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Reading medical images to detect and diagnose diseases is often difficult and has 
large inter-reader variability. To address this issue, developing computer-aided detection 
and diagnosis (CAD) schemes or systems of medical images has attracted broad research 
interest in the last several decades. Despite great effort and significant progress in 
previous studies, only limited CAD schemes have been used in clinical practice. Thus, 
developing new CAD schemes is still a hot research topic in medical imaging informatics 
field. In this dissertation, I investigate the feasibility of developing several new innovative 
CAD schemes for different application purposes. First, to predict breast tumor response 
to neoadjuvant chemotherapy and reduce unnecessary aggressive surgery, I developed 
two CAD schemes of breast magnetic resonance imaging (MRI) to generate quantitative 
image markers based on quantitative analysis of global kinetic features. Using the image 
marker computed from breast MRI acquired pre-chemotherapy, CAD scheme enables to 
predict radiographic complete response (CR) of breast tumors to neoadjuvant 
chemotherapy, while using the imaging marker based on the fusion of kinetic and texture 
features extracted from breast MRI performed after neoadjuvant chemotherapy, CAD 
scheme can better predict the pathologic complete response (pCR) of the patients. 
Second, to more accurately predict prognosis of stroke patients, quantifying brain 
hemorrhage and ventricular cerebrospinal fluid depicting on brain CT images can play an 
important role. For this purpose, I developed a new interactive CAD tool to segment 
hemorrhage regions and extract radiological imaging marker to quantitatively determine 
the severity of aneurysmal subarachnoid hemorrhage at presentation and correlate the 
xvi 
estimation with various homeostatic/metabolic derangements and predict clinical 
outcome. Third, to improve the efficiency of primary antibody screening processes in 
new cancer drug development, I developed a CAD scheme to automatically identify the 
non-negative tissue slides, which indicate reactive antibodies in digital pathology images. 
Last, to improve operation efficiency and reliability of storing digital pathology image 
data, I developed a CAD scheme using optical character recognition algorithm to 
automatically extract metadata from tissue slide label images and reduce manual entry 
for slide tracking and archiving in the tissue pathology laboratories.   
In summary, in these studies, we developed and tested several innovative approaches to 
identify quantitative imaging markers with high discriminatory power. In all CAD 
schemes, the graphic user interface-based visual aid tools were also developed and 
implemented. Study results demonstrated feasibility of applying CAD technology to 
several new application fields, which has potential to assist radiologists, oncologists and 
pathologists improving accuracy and consistency in disease diagnosis and prognosis 
assessment of using medical image. 
1 
Chapter 1: Introduction 
 
1.1 Background 
Computer-Aided Detection and Diagnosis, known as CAD, involves the 
application of computerized analysis to assist the radiologist in more accurately and 
efficiently reading and interpreting different medical images. CAD popularity is growing 
in the last two decades and is becoming an important area of research in medical imaging 
informatics field, which aims to assist clinicians (i.e., radiologists and pathologists) in 
reading and interpreting medical images for disease detection and diagnosis. 
Traditionally, the clinicians are subjected to do the interpretation process and not always 
make the optimal use of the data acquired by an imaging device [1, 2]. However, there is 
a number of limitations for the clinicians to do the image processing and feature or pattern 
analysis in reading medical images because (1) human eye and brain may not be able to 
reliably detect and compare many image features among different images in a large scale 
dataset, and (2) there is large intra- and inter-reader variability in reading and interpreting 
medical images due to the different training and clinical practice experience of different 
clinicians, [3-5]. In order to address these issues or challenges, many researchers have 
been working to develop and apply image processing techniques and CAD systems 
aiming to assist clinicians (i.e., radiologists and pathologists) to more accurately read and 
diagnose medical images. CAD systems with the help of medical image processing 
techniques are able to modify the image presented to the readers in different ways such 
as enhancing the abnormalities or segmenting a specific lesion and presenting information 
regard the lesion to assist radiologists in reading medical images. For example, computer-
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aided detection (CADe) systems are developed to detect and mark regions of 
abnormalities to alert radiologists to pay more attention to look and analyze these regions 
during image interpretation, while computer-aided diagnosis (CADx) aims to assist 
clinicians in diagnosis of diseases and staging of disease severity or types. Some 
integrated CAD schemes use CADe to detect and identify the abnormal regions and then 
used CADx to provide quantitative information and analysis of the detected regions. CAD 
systems have been widely investigated and developed using variety of image modalities 
such as conventional digital X-ray images (i.e., mammography), magnetic resonance 
imaging (MRI), computed tomography (CT), ultrasound and digital pathology (DP) 
images to detect and diagnose many diseases including cancers such as breast, brain, lung, 
colon cancer and etc. Different tasks such as segmentation of region of interest and 
abnormalities (i.e., tumor, hemorrhage, cells), classification of malignant and benign 
lesions and prediction of treatment response can be conducted using CAD schemes. 
For example, in CAD of breast cancer, Dheeba et al proposed a CAD scheme for 
detecting breast cancer in mammograms using particle swarm optimized wavelet neural 
network [6], Sun et al, applied a three-class classification approach by using a two-stage 
classifier combined with support vector machine (SVM) learning algorithm to classify 
breast tumors detected on mammograms [7], Song et al investigated and compared the 
efficiency of CAD systems for MRI and other breast imaging modalities in the assessment 
of tumor extent, lymph node status in patients with invasive breast cancer [8], Yuan et al 
applied a multimodality CAD scheme that combines image information from full-field 
digital mammography (FFDM) and dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI) for breast tumor or lesion classification [9]. These studies 
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demonstrated that applying CAD systems of different types of medical images using the 
advanced image processing and machine learning technologies may play an important 
role to automatically segment, detect, and classify abnormalities to help more accurately 
and robustly diagnose human diseases using medical images.  
 
1.2 Medical Imaging Modalities  
The overall aim of medical imaging can be summarized under several general 
headings. Human with cancer or other diseases who need immediate treatment requires 
medical imaging to help clinicians make correct diagnosis and select optimal treatment 
options. Imaging modalities play an important role in all aspects of disease treatment, 
including screening, detection, diagnosis, image-guided biopsy, treatment planning, 
outcome assessment and follow-up examinations [10]. Different imaging modalities are 
used for different disease, mammography is used as the standard techniques for breast 
cancer patients, colposcopy images are used for cervical cancer patients, CT images 
detect the lung cancer and digital pathology images are used by pathologists for detecting 
tumor cells and diagnosing tissue specimens. In this dissertation, I developed and 
evaluated CAD schemes of three different image modalities including MRI of breast, CT 
images of brain and digital pathology images of cell and tissue specimens. The basic 
imaging characteristics are described in the following subsections. 
 
1.2.1 Magnetic Resonance Imaging (MRI) 
Mammography and ultrasonography are the standard imaging techniques for the 
detection and characterization of breast tumors, while mammography conceives tissue 
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density differences and ultrasonography demonstrates the difference between solid 
masses and cysts. Mammography sensitivity, when performed optimally, is between 69 
and 90% [11] while the specificity ranges from 10-64% [12].  Observer error, suboptimal 
technique, and large heterogeneity of the tumor and surrounding fibro-glandular tissue 
are the cause of low sensitivity and specificity of mammography.  
Although mammography is well recognized as the most cost-effective imaging 
modality for breast cancer screening and early detection, the performance (including both 
sensitivity and specificity) of screening mammography is not satisfactory [13,14] in 
particular for younger women with dense breast tissues. As a result, other new imaging 
modalities have also been developed and tested for improving breast cancer screening 
and detection. Among them, dynamic contrast-enhanced breast magnetic resonance 
imaging (DCE-MRI) has shown superior sensitivity in detecting mammography-occult 
cancers and is recommended by the American Cancer Society as an adjunct screening 
tool to mammography for women at an elevated breast cancer risk (e.g. >20–25% of 
lifetime risk) since 2007 [15]. Currently, breast DCE-MRI has been playing an important 
role in the clinical management of breast cancer in screening, diagnosis and assessment 
of treatment efficacy [16, 17].  
 
1.2.2 Computed Tomography (CT) 
Computed tomography (CT) is a medical imaging procedure that uses ionizing 
radiation to produce cross-sectional images of the human body. The method by which x-
rays are produced within a CT scanner is similar to general X-ray radiography. However, 
CT scanners have the capability to produce three-dimensional images unlike the two-
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dimensional planar X-ray projection images seen in most radiography studies. Computed 
tomography plays a very important role in diagnoses of many diseases and has been used 
in a variety of medical imaging procedures because of its unique ability to offer clear 
images of bone, muscle, blood vessels, and different types of tissue. Where other imaging 
techniques are much more limited in the types of images they can provide, the role of CT 
in the clinical setting is extensive. It can be used to plan certain surgeries, guide biopsies, 
measure bone mineral density, detect injuries to internal organs, and has proven to be a 
valuable tool for the diagnosis and treatment of many musculoskeletal disorders. CT 
imaging is even used for the diagnosis and treatment of certain vascular diseases. 
Probably the most important aspect of CT however, is its role in cancer detection, 
diagnosis and assess treatment efficacy. It allows physicians to accurately detect and 
locate different types of cancers and plays an important part in radiation treatment 
planning process. The importance of CT technology is without a doubt a vital aspect for 
the diagnosis of diseases and treatment of patients. As the advancements in developing 
new CT imaging technology and novel imaging procedures (i.e., thin slice, low dose and 
perfusion imaging), patient care will continue improving. 
 
1.2.3 Digital Pathology (DP) 
Pathology provides a ground-truth in disease diagnosis. In order to improve 
efficacy of disease diagnosis, digital pathology has been attracted broad research interest 
and developed quickly in medical imaging field. Specifically, instead of visually 
examining pathological specimens under optical microscopes, digital pathology creates 
an image-based information environment enabled by computer technology that enables 
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the acquisition, management and interpretation of pathology information generated from 
digitized images of tissue specimens placed on the glass slides. Whole slide scanner 
technology has been increasingly used in the pathology laboratories and a large number 
of tissue slides are being scanned and processed in recent years. It is well known that 
useful information is in pathology images and digital pathology has the potential to help 
improve efficiency of clinical workflow and provide potential of quantitative feature 
analysis to improve diagnostic accuracy. Additionally, it can also reduce the need for 
storing large number of glass slides on-site and the risk of the physical slides getting 
broken or lost. All images and data can be stored digitally in the computer database, which 
can also be much easy to retrieve by physicians for disease diagnosis and conducting 
research or educational purpose by medical researchers. 
 
Due to colorless and transparency of a large number of cells, histological sections 
have to be stained in some ways to be visible. Different staining techniques such as non-
specific, staining most of the cell in the same way, or selectively staining of particular 
chemical groupings of molecules within cells and tissues are available and used in clinical 
practice. Staining process work by using a dye and counterstain which dye stains some 
of the cell’s components as a bright color and counterstain stains the rest of the cell in a 
different color. Acidic dyes react with cationic or basic components in cells. Proteins and 
other components in the cytoplasm are basic and will bind to acidic dyes. 
The most commonly used stain in histology is called Hematoxylin and Eosin 
(H&E). H&E contains two dyes of hematoxylin and eosin which eosin act as an acidic 
dye, which is negatively charged and stains the basic structures into red or pink. 
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Hematoxylin act as a basic dye and is used to stain acidic structure into a purplish blue. 
Thus, the nucleus is stained purple in the H&E staining process. Figure 1 demonstrated 
an example of H&E staining. 
 
 
Figure 1. H&E staining example. 
 
1.3. Machine Learning 
Machine learning is a field that focuses on the construction of algorithms to make 
predictions based on training data. A machine learning task aims to identify (to learn) a 
function f that maps the input domain X (of data) onto output domain Y (of possible 
predictions) [18]. Functions f are chosen from different function classes, dependent on 
the type of learning algorithm that is being used. Mitchell defines "learning" as follows: 
"A computer program is said to learn from experience E with respect to some class of 
tasks T and performance measure P, if its performance at tasks in T, as measured by P, 
improves with experience E" [19]. The performance measure P tells the researchers 
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quantitatively how well a certain machine learning algorithm is performing. For a 
classification task, the accuracy of the system is usually chosen as the performance 
measure, where accuracy is defined as the proportion for which the system correctly 
produces the output. Experience E that machine learning algorithms undergo are datasets. 
These datasets contain a set of examples that are used to train and test these algorithms. 
 
Machine learning can be accomplished using either a supervised or an 
unsupervised approach. In supervised learning, the system receives a dataset with 
different example parameter values and decisions/classification, from which it infers a 
mathematical function, which automatically maps an input signal to an output signal. 
Thus, it figures out what it is supposed to do. The supervised learning method was used 
in all the studies mentioned in this dissertation. 
Unsupervised learning, on the other hand, means that the system acts and observes 
the consequences of its actions, without referring to any predefined type cases other than 
those previously observed. This is pure 'learning by doing' or trial-and-error. Compared 
to supervised learning, unsupervised methods typically perform poorly in the beginning, 
when they are untuned, but as they tune themselves, performance increases. It can be 
argued that using unsupervised learning, a classifying system should be able to set up 
hypotheses that no human can figure out, due to their complexity. If unsupervised 
methods were used for the studies in this dissertation, the machine learning systems 
would have to find out the learner stage hypothesis all on its own, which would probably 
require much more training data than is available.  
To evaluate classifier performance given by a machine learning scheme, either a 
special testing dataset or a cross validation technique may be employed. A test dataset 
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contains pre-classified data different to those in the training dataset, and is used only for 
evaluation, not for training. If data are scarce, it is sensible to use cross-validation in order 
not to waste any data, which could be useful to enhance classifier performance; all data 
are used both for training the classifier and for testing its performance. 
More data do not necessarily mean better classifier performance. Even though the 
classifier becomes better on the training set it could actually perform worse on the testing 
data. This is due to the overfitting of the classifier transfer function, so that it fits too 
tightly to the training data and the border between classes is jagged rather than smooth, 
unlike how it usually should be. 
Although a large number of machine learning classifiers have been developed and 
are currently available, my studies mainly selected and used following machine learning 
algorithms or classifiers, which are Support Vector Machines, k Nearest Neighbor, 
Artificial Neural Network and Decision Tree. The basic learning concept and 
characteristics of these machine learning classifiers are described briefly as below: 
1.3.1 Support Vector Machines 
Support Vector Machines (SVMs) are one of the most popular classification 
algorithms to perform supervised classification over the dataset [20]. The aim of SVM is 
to find the most optimal classification function that differentiates between units of classes 
in training data. With a linearly separable dataset, the most optimal classification function 
can be decided by constructing a hyperplane which maximizes the margin between two 
datasets and thus creates the largest possible distance between datasets. Figure 2 
demonstrates the visualization of SVM strategy.  
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Figure 2. Creating the optimal separating hyperplane with the use of support vectors to 
classify the two classes.   
 
The idea behind SVMs is that by finding the maximum margin, which represents 
the most optimal hyperplane and has the best generalization ability that it can reach. This 
results in the best classification performance for both the training data as well as future 
data. Thus, a Support Vector Machine is strictly not a machine, but a simple and powerful 
algorithm. 
 
1.3.2 K Nearest Neighbor 
k-Nearest-Neighbor classification, or kNN, is another popular machine learning 
algorithm that localizes a group of k objects in a training case that has the closest 
proximity or similarity to the test object, and then assigns a label derived from the 
prevalence of a class in the closest proximity. Three important components are needed 
for this algorithm: a group of labeled objects; a proximity metric; and the number k of 
nearest neighbors [21]. A popular proximity metric that is used for kNN classification is 
"Euclidian Distance" [22]. Other metrics exist for defining the distance between instances 
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of a dataset. Examples include the Minkowsky, Camberra or Chebychev metrics [23] 
although often weighing strategies are used that alter the voting influence for more 
accurate results. 
 
1.3.3 Artificial Neural Network 
Neural networks have gained widespread recognition as an effective machine 
learning algorithm by outperforming many algorithms such as Support Vector Machines 
in various relevant applications such as pattern recognition [20, 24]. A neural network is 
an architecture that comprises of units named neurons. These architectures usually consist 
of three different layers: the input layer which contains the input feature vector; the output 
layer that consists of the neural network response; and the hidden layer that contains the 
neurons that connect to both the input and output. An example of a neural network is 
illustrated in Figure 3. This artificial neural network, called a Feed-forward neural 
network, only allows signals to travel from input to output. 
 
Figure 3. An example of Neural Network design consisting of 3 layers of Input, Hidden 
and Output Layer. 
 
12 
Artificial neural networks consist of three fundamental characteristics: the 
network architecture; input and activation functions; and the weight of input connections. 
The network architecture and functions are chosen at the initial stage and remain the same 
during training. The performance of the neural network is reliant on the value of the 
weights. The weights are tuned during training so that a certain output is achieved. ANN 
can be trained using a multitude of different training programs [25]. A very prominent 
training method is the back-propagation algorithm [26]. Other techniques include the 
weight-elimination algorithm that automatically infers the network topology, and genetic 
algorithm that tries to derive the network architecture and train its weights through 
competition and evolution of GA-chromosomes through multiple generations [27- 29]. 
 
1.3.4 Decision Tree 
The Decision tree algorithm comprises of trees that categorize data by looking at 
feature values. Every node in a decision tree depicts a feature that has to be classified, 
and the tree branches depict values that are considered by such a node. A survey of 
existing work on decision tree construction is done by Murthy [30], who describes the 
use of decision trees in multiple disciplines such as statistics, pattern recognition and 
machine learning. One of the most popular decision tree algorithms in literature is the 
C4.5 algorithms by Quinlan [31], an improved version of the earlier decision tree 
algorithm by Quinlan, the ID3 [32.]. C4.5 uses a divide and conquer strategy to grow a 
tree, selecting one feature with a minimum of two outcomes that divides the set of samples 
most effectively. When all instances in a certain set belong to one class, or the set size is 
too small, a label is assigned to a decision tree leaf equal to the most popular class label 




Figure 4. Example decision tree.  
 
The highest decision node is called the root node. The feature that can sort the 
data most effectively is chosen as the root node. This strategy is duplicated for each sub-
division of the training data, until all data is divided into specific class batches. 
Determining which feature sorts the training data most effectively can be done through 
many techniques such as the "Gini Index" [33] "Information Gain" [34], or the "ReliefF 
Algorithm" [35]. Even though each of these techniques differs from the other, a survey 
of decision tree algorithms by Murthy showed that no single best method exists for 
determining the best sorting feature [30]. However, for a specific dataset, comparing 
individual techniques may provide useful insights for the choice of sorting feature. 
In order to build right sized trees, Breiman et al. [33] proposed "pruning", a 
technique that is used to reduce the complexity of decision trees by removing sections of 
a tree that provide little information for the classification of instances. To prevent 
overfitting training data, two common approaches can be used: (1) stopping the training 
algorithm before a perfect fit is reached; and (2) pruning the decision tree. A survey of 
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popular pruning methods is presented by Elomaa, who concludes that no single best 
pruning method exists [36].  
 
1.4 Active Learning 
Semi-supervised learning is another machine learning class beside supervised and 
unsupervised learning. As mentioned earlier, in supervised learning, we learn a mapping 
from observation to predicted output from a set of (input, output) pairs: each training 
input has an associated output. In unsupervised learning, there are no known outputs, and 
the goal is to discover structure in the set of (input) points. To take advantages of both 
learning approaches, the semi-supervised learning includes a set of (input, output) pairs 
with the labeled truth and another separate set of unlabeled (input) data. The goal is then 
to use the structure of the unlabeled data points to learn a better mapping than what we 
would get from labeled data alone. In a supervised machine learning task, we need to 
obtain labeled data to train a model. In most medical imaging related studies, obtaining 
the large image dataset with verified label (ground truth) is quite difficult and expensive 
in terms of time or labor of the clinicians. Thus, the researchers may choose to label a 
subset of the available data, but the choice of the subset will affect the quality and 
performance of the final machine learning model or classifier. The question, then, is how 
to optimally select the subset of data that will achieve the best model performance. The 
importance of active learning emerges in applications that deal with large amounts of 
data; since labeling such data can be very costly and exhausting. Active learning is an 
iterative machine learning algorithm in which the main issue is to evaluate the 
informativeness of an unlabeled instance. The active learner is a classifier that is initially 
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trained on a few labeled instances. Then, iteratively, by its knowledge derived from the 
labeled data it requests a label for one of the instances of the unlabeled pool of data. 
Successful active learning should lead to a significant reduction of the amount of training 
data needed for a supervised learning task with no significant reduction of the machine’s 
performance over a machine trained with a fully-labeled dataset. We indicate most of 
supervised machine learning algorithms as passive learning in terms of fully-labeled 
training data. The efficiency of active learning has been qualified by two approaches. The 
more common approach is the reduction of training data required to reach a certain level 
of performance. The other approach is to increase the performance of the model for a 
certain amount of training data [37].  
The applicability of either of these approaches depends on the established image 
datasets. Active learning has been studied in many different contexts [38] that provide a 
comprehensive literature review on the subject. For example, application of speech 
recognition [39] employed active learning to select a limited subset of utterances to 
transcribe from a large amount of un-transcribed utterances. It reduced the number of 
utterances needed for transcribing by 60% to achieve the same recognition accuracy 
obtained using random sampling. Another application of active learning is in message 
filtering. For instance, in spam filtering applications, trustworthy labels for messages can 
be costly to acquire. Sculley reports that online active learning can significantly reduce 
labeling and training costs while maintaining high levels of filtering performance [40]. 
Active Learning has been also employed for the task of classification for documents or 
media like images, audio and videos. For the classification of media not only the 
16 
annotation can be very time consuming and tiring can also be mentally challenging (i.e., 
sexual child abuse). Figure 5 illustrates the active learning cycle in this problem domain. 
 
Figure 5. Active learning cycle for image classification task. The cycle starts by 
labeling few examples as initial seeds then active learner model is created. By applying 
query strategy on the unlabeled pool of data, the active learner asks the human 
annotator for the label of the most informative example. The new labeled example will 
then be added to the training set. 
 
1.5 Objective of Studies 
As previously mentioned, CAD systems of medical images have been developed and 
tested for different tasks such as segmentation and detection of abnormalities, diagnosis 
of diseases, prediction of prognosis and assessment of treatment efficacy to help provide 
physicians new quantitative image feature analysis or decision-making supporting tools 
in current and future clinical practice. Despite great research effort, many technical and 
clinical challenges remain in developing CAD schemes and expanding CAD application 
in many different clinical application fields. The goal of this dissertation is to investigate 
several new and novel CAD concepts and approaches, as well as to develop and test 
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feasibility of applying these CAD approaches to several new clinical applications using 
breast MRI, brain CT and digital pathology images. The study hypothesis is that by 
developing these new CAD schemes, we can identify new quantitative imaging markers, 
provide clinicians new visual-aid or decision-making supporting tools to better read and 
interpret medical images, and improve efficacy of using digital pathology technology in 
the clinical practice. Developing and implementing these new CAD schemes or tools can 
have potential to help improve accuracy and consistency of the clinicians in disease 
detection, diagnosis, and patient management and treatment. 
1.6 Organization of Dissertation   
To test the study hypothesis described in previous subsection, I have conducted 
many studies in the last several years in University of Oklahoma and Roche Company. 
In this dissertation, I report four applications of developing CAD schemes using three 
medical imaging modalities (MRI, CT and Digital Pathology images) to segment disease 
regions (ROIs) and apply different machine learning algorithms to perform the 
classification tasks (Chapter. 2,3,4,5) and an application of developing optical character 
recognition scheme to help convert analog information to digital information and 
realizing storage of digital cell or tissue specimen images in pathology laboratory 
(Chapter 6). Specifically, in Chapter 2, a new quantitative global breast MRI feature 
analysis scheme was developed to predict tumor response to the neoadjuvant 
chemotherapy using breast MRI images acquired pre-therapy. In Chapter 3, a new 
quantitative image processing and feature analysis method was developed and evaluated 
to predict the pathologic complete response of breast cancer patients who underwent 
neoadjuvant chemotherapy using images acquired post-therapy. In Chapter 4, a 
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computer-aided detection tool was developed to segment and quantify intracranial 
radiologic markers using brain CT images. In Chapter 5, a computer-aided detection 
scheme was developed to automatically identify the non-negative digital pathology slides 
for IHC assay development. In Chapter 6, a new CAD scheme with optical character 
recognition algorithm and graphical user interface named Tissue Slide Reader was 
developed and tested. Last, in Chapter 7, a summary of these new CAD schemes and their 
future application potentials are discussed, which generate the conclusion of this 
dissertation including the future work of this candidate. 
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Chapter 2:  Developing a New Quantitative Global Breast MRI 
Feature Analysis Scheme to Assess Tumor Response to Chemotherapy 
 
2.1 Introduction 
Among the existing imaging modalities of breast cancer detection, diagnosis, and 
prognosis assessment, dynamic contrast enhancement (DCE) breast magnetic resonance 
imaging (MRI) has superior capability and performance. For example, one review article 
analyzed five prospective clinical studies and revealed a comparison result in which the 
cancer detection sensitivities were 40% and 81% for mammography and breast MRI, 
respectively [41]. Another large clinical study involving 2809 women with elevated 
breast cancer risk also reported that using breast MRI enabled detection of 79% (41/52) 
mammography-occult cancers [42]. Hence, using breast MRI could detect a significantly 
greater number of cancers than mammography. As a result, breast DCE-MRI has been 
recommended by the American Cancer Society as an adjunct screening tool to 
mammography for women with lifetime breast cancer risk greater than 20–25% since 
2007 [15]. In addition, breast MRI has played an important role in classifying breast 
tumors (ie, ductal carcinoma in situ [DCIS] or invasive ductal carcinoma [IDC] with and 
without metastasis positive lymph nodes [43]) and evaluate the tumor response to 
chemotherapy by comparing two sets of breast MR images acquired pre- and post-
chemotherapy [17].   
In current practice, advanced stage breast cancer patients with large breast lesions 
are treated with neoadjuvant (preoperative) chemotherapy before surgery. Based on the 
tumor response to the neoadjuvant chemotherapy, a breast cancer patient may receive 
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breast-conserving surgery instead of mastectomy [44-46] or avoid the surgery due to the 
pathological complete response (pCR) [47, 48], which would improve the life quality of 
breast cancer patients. Tumor response to the chemotherapy is typically evaluated by 
comparing tumor size and kinetic feature variation using breast MRI examinations taken 
pre- and post-chemotherapy based on the RECIST guideline [49]. However, due to the 
large heterogeneity of breast tumors, the response to the neoadjuvant chemotherapy 
varies widely in different patients [50]. Hence, in order to assist clinicians in making an 
optimal treatment plan for the individual patients early and/or reduce the toxicity or other 
side effects of the patients who do not receive significant benefit from the neoadjuvant 
chemotherapy, developing a new clinical marker that allows more accurate prediction or 
assessment of tumor response early may have high clinical impact. For that purpose, we 
developed and tested a new quantitative kinetic image feature analysis-based CAD 
scheme using breast MR images acquired before the patients participated in the 
neoadjuvant chemotherapy to predict tumor response to the neoadjuvant chemotherapy 
[51]. From the segmented breast lesions, the scheme computed kinetic image features of 
the lesions and assessed the likelihood of tumor response to the neoadjuvant 
chemotherapy using a multi feature-based artificial neural network. 
Despite encouraging results in our preliminary study, application of the scheme 
can be limited or less robust due to the difficulty in accurately defining and/or segmenting 
the breast lesions, in particular the subtle and/or diffuse lesions without a solid lesion 
boundary. Recently, studies reported by several groups [52,53] demonstrated that the 
global background parenchyma enhancement (BPE) features extracted from the entire 
breast MR images can be used to assess breast cancer risk [52] and improve accuracy in 
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classifying between malignant and benign breast lesions [53]. Hence, based on previously 
published works, the objective of this study was to develop a new quantitatively global 
kinetic image feature analysis-based CAD scheme without lesion segmentation and test 
the feasibility of applying this new scheme to assess tumor response to the neoadjuvant 
chemotherapy. 
 
2.2 Materials and Methods 
2.2.1 DCE-MRI Image Dataset 
The study protocol including an image data collection and data analysis method 
was approved by our Institutional Review Board. In this retrospective study, the image 
data were collected from the existing cases stored in the clinical Picture Archiving and 
Communication System (PACS). The informed consent of the patients was waived. The 
dataset includes the deidentified breast MR images acquired from 151 breast cancer 
patients. Each patient had two sets of breast DCE-MRI examinations taken before and 
after neoadjuvant chemotherapy. The average time difference between two MRI 
examinations is around 5 months (or 157 days). All MRI examinations were performed 
using a 1.5T GE Excite MRI scanner in 2008 and 2010. In each MRI examination, five 
sets of axial images were scanned and acquired. The first one is a pre-contrast scan of 
two breasts. Approximately 3 minutes after intravenous administration of 0.1 mmol/kg 
body weight OptiMARK gadolinium, four sets of post-contrast scans started to acquire 
four sets of new axial images. Each image slice has 512 × 512 pixels with a pixel size of 
0.6445 × 0.6445 mm and a slice thickness of 4 mm. 
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Among the 151 patients, 63 were assigned to the complete response (CR) group 
and 88 were categorized as the partial response (PR) group. According to RECIST 
guidelines, in the CR group the kinetic enhancement signals (or contrast-enhanced pixels) 
inside the tracked breast tumors depicting the first set of breast MR images acquired pre-
chemotherapy become undetectable in the second set of breast MR images acquired post-
chemotherapy, while in the PR group the contrast-enhanced pixels inside the tumor 
regions decrease by more than 30% between the post- and pre-chemotherapy breast MR 
images. Figure 6 shows three examples of two matched breast MR image slides acquired 
pre- and post-chemotherapy of three patients. In one CR case (Fig. 6 a, b), the contrast-
enhanced pixels almost disappear inside the target tumor region depicted on the post-
chemotherapy breast MR image. In the first PR case (Fig. 6 c, d) a solid tumor has contrast 
enhanced pixels surrounding a tumor boundary and a big necrotic center region. After 
neoadjuvant chemotherapy, although the tumor diameter was reduced or “partially 
responsive,” the central necrotic region of the tumor also disappears and the active 
contrast enhancement volume increases after the neoadjuvant chemotherapy. The second 
PR case (Fig. 6 e, f) shows the lesions with diffused enhancement on breast MR images 
acquired pre- and post-chemotherapy. 
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Figure 6: Three examples of showing two matched breast MR image slides acquired 
from pre- and post-chemotherapy of one CR case (a) and (b), one PR case with solid 
contrast enhanced tumor (c) and (d), and one PR case with the diffused lesion 
enhancement (e) and (f). 
 
In this dataset, the age of the patients ranged from 25 to 76 years old. The average 
age and standard deviation are 47.4±11.2 and 49.2±10.4 for CR and PR patient groups, 
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respectively, which indicate that the majority of women whose breast DCEMRI 
examination images were selected in this study are relatively younger (<50 years old).  
Table 1 summarizes the basic tumor characteristics between the CR and PR case 
groups. The majority of tumors were diagnosed as invasive ductal carcinoma (IDC) with 
or without associated DCIS. Finally, the axial view of the breast MR images acquired 
pre-chemotherapy of each patient was used and analyzed in this study. The goal of this 
study was to use the global kinetic image features computed from the pre-chemotherapy 
breast MR images only to build a machine-learning classifier or model to assess tumor 
response to the neoadjuvant chemotherapy.  
 
Table 1: Distribution of Tumor Subtypes in Both CR 
Tumor characteristics CR PR 
Number of solid tumors 25 43 
Average size of solid tumors 
Number of diffused tumors 38 45 
Tumor pathology subtypes 
Invasive ductal carcinoma (IDC) 26 27 
IDC and DCIS 28 45 
Invasive lobular carcinoma (ILC) 2 1 
ILC and DCIS 2 1 
Infiltrating carcinoma 0 1 
Invasive mammary carcinoma 0 3 
Poorly differentiated carcinoma 5 10 
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2.2.2 Quantitative Global Kinetic Image Feature Computation 
In order to automatically compute global contrast enhancement features, we 
applied a CAD scheme of breast MR images that has been developed and to segment the 
breast region depicted on each breast MR image by removing all pixels in the air 
background and behind the chest wall or pectoralis muscle. The details of this CAD 
scheme have been reported in our previous publication [51]. In brief, the CAD scheme 
uses the following four image processing and feature computation steps: 1) applying a 
threshold method to remove all pixels in the air background of each image; 2) detecting 
the chest wall depicted on each breast MR image to remove all pixels behind the chest 
wall (Figure. 7); 3) performing image registration and subtraction of two sets of matched 
breast MR image slices acquired in two breast MRI scans performed pre- and post-
injection of gadopentate dimeglumine (Gd-DTPA) contrast agent; and 4) computing a set 
of relevant kinetic image features from segmented breast regions depicted on each 
subtraction image. By applying this CAD scheme to all breast MR image slides, we are 





Figure 7: An example to show chest wall detection and breast region segmentation, in 
which (a) shows an original image slice marked by two CAD scheme detected lines to 
segment between two breasts and chest regions, and (b) shows the final segmented 
breast regions, which are used to compute the BPE features. 
 
Our CAD scheme initially computed a set of 10 kinetic or contrast enhancement 
image features from the subtraction images of two sets of registered images acquired pre- 
and post-injection of contrast agent (as shown in Table 1). Specifically, these features 
include: F1: the average contrast enhancement value (EV), which is simply computed as 
an average of the pixel value of all pixels inside the segmented breast volume; F2: 
standard deviation and F3: skewness of the contrast enhancement values, which are two 
features that measure the heterogeneity of contrast enhancement of the pixel values; F4: 
the maximum contrast enhancement value inside the whole breast volume. In addition, 
CAD scheme sorted the contrast enhancement values from the maximum to the minimum, 
which are computed from the whole breast volume, and then computed two new features: 
F5: the average contrast enhancement value among the pixels listed in the top 1%, and 
F6: in the top 5% of the sorting list. In a previous study, using these two average contrast 
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enhancement values could have higher discriminatory power to assist classifying between 
malignant and benign breast lesions than using the average or the maximum contrast 
enhancement value computed from the whole breast regions [54]. In addition, the CAD 
scheme also computed four features representing the bilateral differences (or the absolute 
subtraction) of two feature values computed from the left and right breast regions (F7–
F10). 
 
2.2.3 Feature Analysis and Performance Assessment 
Next, from the initial feature pool of 10 contrast enhancement image features 
(Table 2), we aimed to select optimal image features and build a machine-learning 
classifier to assess the likelihood of the breast tumors being completely responsive to the 
neoadjuvant chemotherapy (CR). For this purpose, we used a publicly available data 
mining and machine-learning software platform, Weka [55], to perform feature selection 
and classifier training and testing tasks. A similar optimization process has been applied 
and tested in our previous study [51]. In brief, we used a specific machine-learning 
classifier, the “Attribute Selected Classifier,” which integrates an artificial neural network 
(ANN) as the base classifier and a Wrapper Subset Evaluator (WSE) to guide feature 
selection from the initial pool of 10 features. This integration takes a search algorithm 
and evaluator next to the base classifier, which makes the feature selection process 





Table 2: Description of 10 computed global kinetic image features. 
Feature Description Feature Description 
F1 Average enhancement value 
(EV) 
F6 Average EV of top 5% 
F2 Standard deviation of EV F7 Bilateral average EV difference 
F3 Skewness of EV F8 Bilateral STD EV difference 
F4 Maximum EV F9 
Bilateral difference of average 
EV of top 1% 
F5 Average EV of top 1% F10 
Bilateral difference of average 
EV of top 5% 
 
Due to the limited dataset size of 151 cases, the classifier was trained using a 
leave-one-case-out (LOCO) method to maximally use all available training cases and also 
minimize the testing bias [57]. In addition, to avoid bias in feature selection, the feature 
selection process was embedded inside the LOCO training and testing iteration loops. In 
each LOCO training and testing process, one case was selected as an independent testing 
case and the remaining 150 cases were used as training cases. The WSE guided feature 
selection method was applied to all 150 training cases to search for optimal features from 
the entire feature pool and train an ANN-based classifier. The trained ANN was then 
applied to one independent testing case and generated a classification score for the testing 
case (ranging from 0 to 1). The higher score indicates a higher probability of the tumor 
responding to the neoadjuvant chemotherapy or being classified into the “CR” class. This 
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LOCO process was repeated 151 times. As a result, 151 classification scores were 
independently generated for all 151 cases in our dataset. In the different LOCO training 
and testing iteration cycles, the potentially different image features may also be selected 
from the initial pool of features and used to build the ANN. 
We then used the area under a receiver operating characteristic (ROC) curve 
(AUC), which was computed using a publicly available maximum likelihood-based ROC 
curve fitting program (ROCKIT, http://www-radiology.uchicago.edu/krl/, University of 
Chicago), as an evaluation index to assess performance of the image features or ANN-
generated classification scores associated with the tumor response to the neoadjuvant 
chemotherapy. The P-values were also computed by the ROCKIT program when any two 
sets of image feature data and/or ANN classification scores were used as input data of the 
ROCKIT program. All statistically significant differences were defined as P < 0.05. We 
compared the discriminatory power of using each individual features (as listed in Table 
1) and the classification scores generated by the multi feature based machine-learning 
classifier (ANNs) using the LOCO validation method. In addition, we applied an 
operation threshold of T = 0.5, which is the middle point of the ANN-generated 
classification scores to generate a confusion matrix from which we computed the overall 
classification accuracy as well as the predictive values of both the “CR” and “PR” classes 






When applying each of 10 individual image features computed in our initial 
feature pool (Table 2) to associate with or classify cases between the CR and PR groups, 
Table 3 shows and compares the computed AUC values. The AUC values ranged from 
0.542±0.047 to 0.734±0.043. Among them, the average contrast enhancement value of 
entire breast volume or regions (F1) and standard deviation (F2) have the highest 
discriminatory power, with AUC >0.7. 
 
Table 3: AUC values of applying 10 individual features (given in Table 1) to classify 
between CR and PR group of cases. 
Feature AUC P-value 95% CI 
F1 0.734±0.043 F6 0.623±0.046 
F2 0.723±0.043 F7 0.572±0.047 
F3 0.695±0.508 F8 0.613±0.046 
F4 0.581±0.047 F9 0.542±0.047 
F5 0.596±0.047 F10 0.542±0.048 
 
Table 4 summarizes the percentage of each of 10 features selected during the 151 
LOCO training and testing iteration cycles in building the ANN-based classifier. Despite 
high AUC values of F2, it was not selected much during LOCO training and testing 
iteration cycles because of high correlation with other features (e.g., its correlation 
coefficient with F1 is 0.984). The top four selected features that were selected 90% times 
in 151 LOCO iteration cycles were the average enhancement value of the entire breast 
area (F1), average of bilateral enhancement value difference between left and right breasts 
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(F7), standard deviation of bilateral enhancement value difference between left and right 
breast (F8), and average of bilateral enhancement value of the top 5% difference between 
left and right breast (F10). This indicates that these four features played the most 
important interaction role in developing our ANN based classification model. Three of 
these features were computed from the bilateral asymmetry of the contrast enhancement 
features computed between the left and right breasts. Although using each individual 
image feature may only have limited discriminatory power (or AUC values), developing 
a multiple feature fusion-based ANN classifier enabled yielding a significantly higher 
assessment performance with AUC = 0.83±0.04 than using each feature individually (P 
< 0.05). Figure 8 shows and compares five ROC curves generated using the classification 
scores generated by the ANN-based classifier and each of four commonly selected image 
features. 
 
Table 4: A list of 9 image features that were selected in LOCO training and testing 
iteration cycles to test 151 testing cases in our dataset. 
Feature Percentage Feature Percentage 
F1 100%(151/151) F6 60%(91/151) 
F2 36%(55/151) F7 100%(151/151) 
F3 0%(0/151) F8 100%(151/151) 
F4 11%(16/151) F9 56%(85/151) 




Figure 8:  Comparison of 5 ROC curves generated using the classification scores of the 
ANN-based classifier (solid curve) and other four individual features (dashed curve). 
 
As an example, Table 5 presents the computed feature values and ANN-generated 
classification scores of three cases (as shown in Fig. 6). The CR case has the highest 
classification score. Except feature F10 of case 3, the trend between ANN-generated 
classification scores and other feature values are also demonstrated. Table 6 shows a 
confusion matrix that was obtained by applying an operation threshold of 0.5 to the 
classification scores generated by the ANN-based classifier. The overall assessment 
accuracy of these two groups of 151 CR and PR cases was 82%, in which 124 cases were 
correctly classified into “CR” and “PR” classes, while the remaining 27 cases were 
incorrectly classified. The predictive values of “CR” and “PR” case groups are 86.0% 






























Table 5: Feature Values of Three Cases with Images Shown in Figure 6. 
Feature Case 1 (up) Case 2 (middle) Case 3 (bottom) 
F1 0.29 0.39 0.6 
F7 0.32 0.66 1 
F8 0.37 0.6 0.76 
F10 0.48 0.83 0.42 
ANN 0.996 0.254 0.045 
 
 
Table 6: A confusion matrix of prediction scores generated using an ANN-based 
classifier that was trained using 4 selected image features. 
                        Prediction Result  
  Actual Cases 
CR PR 
CR 43 20 
PR 7 81 
 
2.4 Discussion 
Since breast MRI is the most popular imaging modality used in current clinical 
practice to assess breast tumor response to neoadjuvant chemotherapy [47, 48], 
developing and applying breast MRI image feature analysis based on the quantitative 
image feature analysis or CAD schemes to assess complete response of the breast tumors 
to the neoadjuvant chemotherapy has been attracting research interest [58, 59]. In this 
Chapter, we report our latest progress to develop and test new quantitative image feature 
analysis schemes to predict breast tumor response to neoadjuvant chemotherapy. Our 
study has a number of unique characteristics. First, we tested the feasibility of whether, 
with the help of automated segmentation of breast regions depicted on the breast MR 
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images acquired before pre-chemotherapy, applying a new CAD scheme and machine-
learning classifier optimized using the quantitative global kinetic breast MR image 
features had potential to generate a useful clinical image marker in assessing tumor 
response to neoadjuvant chemotherapy. Our study results support the hypothesis that the 
global background parenchymal enhancement (BPE) of breast MRI carries useful clinical 
information, which may be used to assess breast cancer risk [52] and classify between 
malignant and benign breast MRI examinations [53]. In this study we demonstrated that 
using BPE-related image features could also effectively assess tumor response to 
neoadjuvant chemotherapy.  
 
Second, unlike many previously developed CAD schemes of breast MR images, 
including our own scheme [51], which computed and used the kinetic image features only 
from the segmented tumor regions, the CAD scheme developed in this study does not 
segment the targeted tumors from the breast MR images. As a result, the new CAD 
scheme is much simpler and probably also more robust to be applied to the different breast 
MR images with diverse clinical patterns because the automated tumor segmentation 
process is not only often complicated, but also difficult and/or not robust, in particular for 
segmenting the diffusive tumors depicted on breast MR images. Although the maximum 
contrast enhancement typically occurs inside a malignant breast tumor as measured by 
feature F4, the study results showed that using F4 did not yield the highest classification 
performance, as comparing several features computed from the global breast MR images 
including average contrast enhancement (F1) and standard deviation of the contrast 
enhancement (F2), which indicates that tumor response to the neoadjuvant chemotherapy 
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depends more on the overall contrast enhancement patterns generated from both tumor 
and background parenchymal tissues. 
 
Third, besides computing the global BPE features from the entire breast MR 
images, we also computed bilateral image features asymmetry between left and right 
breasts. We observed that, unlike in assessing breast cancer risk [60], the computed 
kinetic enhancement feature difference between two bilateral breast MR images is 
relatively bigger and classification performance of using such a single feature is lower 
than using the global BPE features. However, these features are still very useful to build 
a highly performing multi feature fusion based classifier. When embedding a WSE inside 
a LOCO-based cross-validation method to select optimal features and optimize the ANN 
classifier, three bilateral BPE kinetic features asymmetry were among the four mostly 
selected image features. The results indicate that the applied machine-learning method 
was effective, which enables selecting and optimally fuse non-redundant image features 
and eliminate the redundant (or highly correlated) features (i.e., features F1 and F2). 
 
Fourth, this was a retrospective study. We applied our CAD scheme to a relatively 
diverse image database randomly collected from the existing clinical database. The 
dataset is relatively balanced in which there are no statistically significant differences in 
patients’ age (P = 0.445) and solid tumor sizes (P = 0.509) between the CR and PR patient 
groups. Hence, our study results support a recently emerged Radiomics concept that 
hypothesized that quantitative image features enabled phenotyping many useful 
biological or gene-expression processes of cancer development and prognosis [61], which 
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provides a simple approach to improve decision-making in cancer treatment at low cost 
[62]. There are also several limitations to this study. For example, 1) this is a laboratory-
based retrospective study using a relatively small data size (with 151 cases). Thus, the 
robustness of our study results needs to be further tested in future studies with large and 
diverse image datasets. 2) Due to our small dataset, our CAD scheme was only trained 
and applied to classify cases into CR and PR groups. 3) To make our CAD scheme simple, 
the scheme does not involve a nonrigid image registration algorithm in an attempt to 
register MR image slices acquired pre- and post-contrast enhancement scans. However, 
due to the lack of ground truth, no accurate nonrigid image registration algorithm is 
available to date. This issue needs to be further developed and investigated. 4) This is a 
single-institution study. The guidelines of neoadjuvant chemotherapy for breast cancer 
patients may vary at different medical institutions. Thus, whether our CAD scheme can 
be optimally applicable to images acquired from other medical institutions also needs to 
be tested in future studies.  
 
In conclusion, in this study we developed and tested a new CAD scheme based 
on the quantitative global kinetic breast MR image feature analysis. From our study we 
demonstrated the feasibility of identifying a new image feature based clinical marker to 
assess breast tumor response to the neoadjuvant chemotherapy. Our study results support 
the new concept of Radiomics [61, 62], in which the high association or supplementary 
information between the quantitative radiographic image features and genomic 
biomarkers can be found. As a result, although many genomic biomarkers have been 
performed in the effort to associate breast tumor response with neoadjuvant 
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chemotherapy, our study suggests that the quantitative image features computed from 
breast MR images also enable providing highly discriminatory information, which can be 
more easily extracted from the existing diagnostic breast MR images and yield high 





























Chapter 3: Prediction of Pathological Complete Response to 
Neoadjuvant Chemotherapy Using Quantitative Breast MR Images 
Feature Analysis 
3.1 Introduction 
Although neoadjuvant chemotherapy is now increasingly used as the first line 
treatment in patients diagnosed with locally advanced breast cancer in order to downstage 
tumor, optimize surgical outcomes and reduce risk of cancer recurrence [63], it also faces 
several clinical challenges. A recent international survey reported that up to 27% of new 
breast cancers are currently treated with neoadjuvant chemotherapy [64]. Due to the large 
heterogeneity of breast tumors, response to neoadjuvant chemotherapy varies 
significantly among the breast cancer patients. In the clinical practice, up to 30% of 
patients underwent neoadjuvant chemotherapy may have pathological complete response 
(pCR) without residual invasive cancer [65]. Studies have also showed that patients with 
pCR had favorable prognosis and/or quite long term disease-free survival (DFS) [66, 67]. 
However, due to the lack of accurate prognostic markers, the majority of pCR patients 
still undergo aggressive surgical interventions, which generates overtreatment and 
unnecessary side effects to the patients. In order to overcome this clinical challenge of 
avoiding or minimizing overtreatment, as well as help establish new personalized cancer 
treatment paradigm, identifying and developing new prognostic clinical markers 
including the imaging markers has been attracting broad research interesting in recent 
years [49, 68]. 
In medical imaging field, dynamic contrast enhanced breast magnetic resonance 
imaging (DCE-MRI) is a routinely used imaging modality to assess breast tumor response 
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to neoadjuvant chemotherapy [68, 69]. A recent clinical trial (NRG-BR005) launched 
within National Clinical Trials Network aiming to explore feasibility of eliminating 
surgery after successful neoadjuvant chemotherapy indicated the need for accurate and 
robust prognostic markers to improve clinicians’ decision-making as it pertains to 
surgical and chemotherapy recommendations [70]. Currently, tumor response to the 
neoadjuvant chemotherapy is typically estimated by the comparing change of the tumor 
size extracted from dynamic contrast enhanced breast magnetic resonance imaging 
(DCE-MRI) examinations of pre and post chemotherapy [44] based on the response 
evaluation criteria in solid tumors (RECIST) guidelines [71]. Accuracy of predicting pCR 
using DCE-MRI and RECIST criteria still remains lower with approximately 50% 
negative predictive value [72]. A recent ACRIN 6657 Trial involving 138 cancer patients 
treated with neoadjuvant chemotherapy reported that the correlation between longest 
diameter of tumors measured from MRI and final pathology size of tumors was 
surprisingly low (r = 0.33). Combining MRI, clinical examination, and mammography 
yielded the highest pCR prediction performance with the area under ROC curve, AUC = 
0.76 [73]. Thus, in order to increase accuracy in predicting pCR using the image features 
or markers extracted from DCE-MRI, more research effort and progress are needed.   
In this study, we hypothesized that using a machine learning approach to optimally 
combine both kinetic and texture based image features computed from DCE-MRI may 
help yield significantly higher performance or accuracy in predicting pCR of breast 
cancer patients underwent neoadjuvant chemotherapy. In order to test our hypothesis, we 
investigated and evaluated a new quantitative image processing and feature analysis 
method to predict pCR. Specifically, we first used a computer-aided detection (CAD) 
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scheme to automatically remove chest wall and segment breast region depicting on breast 
MR images acquired after performing the neoadjuvant chemotherapy and compute a set 
of kinetic and texture-based image features. Next, a random selection method was used 
to generate new dataset from the initial dataset. Last, three different machine learning 
algorithms were trained and tested using ten-fold cross validation method to predict pCR 
of breast cancer patients underwent neoadjuvant chemotherapy. Four parameters were 
computed from the result of the prediction to assess the performance of using all features. 
Figure 9 demonstrates the diagram for this study. The details of our study and 
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Figure 9: The diagram of subsequent steps in this study. 
              
3. 2 Materials and Methods 
3.2.1 Breast MR Image Dataset 
A retrospectively collected breast DCE-MRI dataset was collected and used in this 
study. The dataset includes images acquired 154 breast cancer patients underwent 
neoadjuvant chemotherapy. Each patient had two subsequent breast DCE-MRI 
examinations taken before and after the neoadjuvant chemotherapy. The average time 
difference between two examinations is 157 days. After neoadjuvant chemotherapy, each 
patient underwent a surgical intervention procedure. Based on the pathologic examination 
reports, the dataset was then divided into two groups of “pathologic complete response” 
(pCR) cases and “non-pathologic response” (non-pCR) cases. Among the 154 patients, 
53 patients were assigned to the pCR group in which no invasive cancer cells or residual 
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malignant lesions were detected in the pathological tests, while other 101 cases were 
assigned to the non-pCR group in which the residual cancer cells were detected and 
reported in the pathological test reports. 
In this dataset, the mean and standard deviations of the patient’s age are 50±9.1 and 
49±11.1 for the groups of pCR and non-pCR cases, respectively. Each MRI examination 
in the originally recorded data include five sets of axial view and two sets of sagittal view 
images acquired before and after the neoadjuvant chemotherapy using a 1.5T GE Excite 
MRI scanner. The five sets of axial view include one acquired pre-injection of 
gadopentate dimeglumine (Gd-DTPA) contrast agent and four series of post injection of 
the contrast agent. From the breast DCE-MRI examination performed after neoadjuvant 
chemotherapy, the first two MR image scanning series namely, the pre- and the first post-
contrast agent injection, were used and analyzed in this study. Each image slice has 
512×512 pixels with the pixel size of 0.58 mm in each direction and slice thickness of 2.6 
mm.   
3.2.2 Image Processing and Feature Computation 
In order to develop a new quantitative imaging marker or prediction model to predict 
pCR cases, this study involves following steps. In brief, a computer-aided detection 
(CAD) scheme developed and reported in our previous studies [51, 74] was first applied 
to automatically detect the chest wall and segment breast region depicted on breast MR 
images. Our CAD scheme include three image processing and feature computation steps 
namely, (1) segmenting breast region by detection of chest wall and removing all regions 
behind the chest wall; (2) applying image registration and subtraction method on the two 
sets of matched breast MR images acquired pre- and the first post-injection of the contrast 
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agent to generate a new set of contrast enhanced image maps; and (3) computing a set of 
image features from the generated image maps. Next, a multi-feature fusion based 
machine learning method was applied to select optimal features and build prediction 
model. Last, the statistical data analysis method was used to assess the performance of 
the CAD scheme and pCR prediction model. The details of each step are presented as 
follows. 
A. Breast region segmentation and image registration 
Our CAD scheme used a region blobbing algorithm to remove any pixels in the air 
background of each image. A series of algorithms including Otsu’s thresholding method, 
morphological operation and region growing algorithms were applied to detect the chest 
wall by generating a separation line and remove any regions (or pixels) behind the chest 
wall from the breast MR images. The area surrounded between the separation line and 
breast skin were defined as the segmented breast region and were used to generate a map 
to be applied on the breast MR images. Next, an image registration algorithm was applied 
to perform a simple subtraction method on two series of the MRI scans acquired before 
and after the injection of the contrast agent. A new series of contrast enhancement image 
maps were generated that include the segmented and registered breast regions. Figure 10 
demonstrates an example of the breast region segmentation process and the generated 
new contrast enhancement image map. 
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Figure 10: An example of the breast region segmentation steps and generating the 
contrast-enhanced image map including (a) the original image, (b) separation line, (c) 
generated mask and (d) the breast region segmented on the contrast-enhanced map. 
B. Image feature computation 
After image segmentation and subtraction to generate the contrast-enhanced image 
maps, CAD scheme computed a total of 38 features including both texture and kinetic 
features from the generated contrast-enhanced images. Among the initial feature pool of 
38 features, 28 were texture-related features computed in three-dimensional (3D) space 
of image maps, which include 17 features derived from gray level co-occurrence matrices 
(GLCM) and 11 features computed from the gray level run length method (GLRLM). 
The GLCM method characterizes the texture of an image by calculating how often pairs 
of pixel with specific values in a specified spatial relationship occur in an image, while 
the GLRLM method measures the size of homogeneous runs for each gray level in the 
image.  
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From the GLCM matrix, CAD scheme computed following texture features, which 
include energy, contrast, homogeneity and correlation as previously defined by Haralick 
et al [75] as: 
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where 𝑔𝑖𝑗 is the ith and jth entry of the GLCM representing a gray-tone intensity 
in the matrices and 𝜇𝑥 , 𝜇𝑦   and 𝜎𝑥 , 𝜎𝑦  are the mean and standard deviation of the 
probability matric, respectively.  
In these features, energy illustrates the textural uniformity of the image, contrast 
measures the difference between the lowest and highest voxels gray tones, homogeneity 
computes the diagonal elements within the displacement vector of the GLCM, and 
correlation describes the linear dependency on the neighboring gray tone intensities. The 
remaining GLCM texture features included entropy, autocorrelation, cluster prominence, 
cluster shade, cluster tendency, dissimilarity, inverse variance, difference entropy, 
maximum probability, sum average, sum entropy, and variance. 
CAD scheme also extracts and computes 11 texture features from the Gray Level Run 
Length matrices (GLRLM) of the segmented breast region in each slice [76]. The 
46 
computed GLRLM features include (1) Short Run Emphasis (SRE), (2) Long Run 
Emphasis (LRE), (3) Gray Level non-Uniformity (GLN), (4) Run length non-uniformity 
(RLN), (5) Run Percentage (RP), (6) Low Gray Level Run Emphasis (LGRE), (7) High 
Gray Level Run Emphasis (HGRE), (8) Short Run Low Gray Level Emphasis (SRLGE), 
(9) Short Run High Gray Level Emphasis (SRHGE), (10) Long Run Low Gray Level 
Emphasis (LRLGE), and (11) Long Run High Gray Level Emphasis (LRHGE). 
 
In addition to two types of texture features, CAD scheme also computed MRI kinetic 
features that are divided into two groups namely, computed from the whole breast region 
and the bilateral difference between left and right breast region. The computed kinetic 
features include: average enhancement, standard deviation, maximum intensity, the 
average enhancement of top 10 percent and average enhancement of top 5 percent. Table 
7 shows the summary of the computed image features. The similar kinetic features 
computed from breast MR images have been applied to assist breast cancer diagnosis 
(i.e., classification between malignant and benign cases) [53] and prediction of breast 












Feature group Description 
1-17 GLCM a 
Contrast, Correlation, Energy, 
Homogeneity1, Homogeneity2, 
Entropy, Autocorrelation, 
Cluster Prominence, Cluster 
Shade, Cluster Tendency, 
Dissimilarity, Inverse Variance, 
Difference Entropy, Maximum 
Probability, Sum Average, Sum 
Entropy, Variance 
18-28 GLRLM b 
SRE, LRE, GLN, RLN, RP, 
LGRE, HGRE, SRLGE, 
SRHGE, LRLGE, LRHGE 
29-33 
Kinetic for the 
Background parenchymal area 
Average intensity, standard 
deviation, maximum pixel 
intensity, average value of top 
1%, and average value of top 
5% of pixel values 
34-38 
Kinetic for absolute 
bilateral difference of BP area 
Average intensity, standard 
deviation, maximum pixel 
intensity, average value of top 
1%, and average value of top 
5% of pixel values 
a GLCM: Gray-Level Co-Occurrence Matrix, b GLRLM: Gray-Level Run Length Matrix 
 
3.2.3 Machine Learning Models and Data Analysis 
In order to fuse multiple features to yield the improved predictive performance than 
using single feature, we applied machine learning methods to build the optimal predictive 
model. Although many different machine learning models have been investigated and 
applied in CAD of medical images, we selected two classification models or classifiers 
that represent different machine or statistical learning concepts aiming to predict pCR of 
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each case underwent neoadjuvant chemotherapy. These two models are 1) fine gaussian 
support vector machine (FGSVM), and 2) weighted K- nearest-neighbor (KNN). In these 
two learning models, the fine gaussian SVM builds a single global optimization function 
to make the finely-detained distinctions between two classes using Gaussian kernel scale; 
while the weighted KNN model builds many local regions based optimization functions 
to distinguish two targeted classes based on the similarity of the local neighbors. 
 
However, the image dataset used in this study is unbalanced between the two 
categories of pCR and non-pCR (53 vs. 101 cases). In order to reduce case election bias 
and more effectively train machine learning models using the balanced image datasets in 
two categories, we applied a computer program to randomly select 53 non-pCR cases 
from the dataset to create a new sub-dataset of 106 cases (53 pCR cases vs. 53 non-pCR 
cases). This computer programs controlled random process is repeated 50 times to 
generate 50 sub-datasets. Using each sub-dataset of 106 cases, we applied a ten-fold cross 
validation method to train and test performance of each machine learning model. This 
training and cross-validation process was repeated 50 times by using 50 sub-datasets to 
assess robustness of the model performance.  
In each ten-fold cross validation, 53 pCR and 53 pCR cases were randomly and 
individually segmented into 10 subgroups. In each training and testing, 9 subgroups were 
used to train the classification models. The remaining subgroup of cases was used as an 
independent dataset to test the classification model and generate the prediction scores. 
After completing this 10-fold cross validation cycle, each case in this dataset has a 
classification ranging from 0 to 1. The higher score indicates the higher likelihood or 
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probability of the case being pCR. Using the classification scores, a publicly available 
receiver operating characteristics (ROC) curve fitting program (ROCKIT, http://www-
radiology.uchicago.edu/krl/,University of Chicago) was applied to compute the area 
under ROC (AUC), which is used as an evaluation index to assess and compare 
performance of each machine learning model. Finally, mean and 95% confidence interval 
of each machine learning model using all 50 datasets were computed. 
3.3 Result 
 
CAD scheme used the new 50 generated datasets based on statistical bootstrapping 
concept to build 2 different classification methods including fine gaussian SVM 
(FGSVM) and Weighted KNN models using all 38 features. Each dataset was used to 
build different machine learning classifier to predict the result of pathology. Table 8 
illustrate the 95% confidence interval (CI) value of the computed AUC value from the 
ROC curve of these classification. It shows that using FGSVM or WKNN both gives high 
95% CI and mean value.  
 
Table 8: Comparison of 95% confidence interval (CI) and mean value of computed 
AUC using different classification methods. 
Classification method AUC (95% CI, mean value) 
FGSVM [0.66, 0.7], 0.68 
WKNN [0.68, 0.71], 0.69 
 
Table 9 demonstrate the highest accuracy, sensitivity and specificity computed 
from the two classification methods using all feature pools. Results show that using fine 
gaussian SVM as the classification to train and test the dataset, yield the highest accuracy, 
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positive predictive value (PPV) and negative predictive value (NPV)of 62% and 80%, 
respectively.  
Table 9: Comparison of three parameters of accuracy, sensitivity and specificity in 
three different classification method. 
Classification method Accuracy PPV NPV 
Fine Gaussian SVM 67% 62% 80% 
WKNN (k=10) 59% 62% 58% 
 
3.4 Discussion 
Neoadjuvant chemotherapy is the first step for treating breast cancer patients with the 
aim of shrinking larger tumor [44, 77-78]. A significant fraction of the patients’ response 
completely to the chemotherapy and the tumors are vanished, while some patients only 
have partial or no response to the neoadjuvant chemotherapy. Although it is 
understandable for patients who have complete response shown in breast MRI acquired 
post-therapy to not undergo for surgery, but the complete disappearance of the tumor or 
malignant cells can only be determined by a comprehensive pathology examination. The 
pathological analysis will be performed on many breast tissue specimens that was 
removed by the surgery to examine whether there are the remaining malignant tumor 
cells. Since patients who have the pCR reported higher survival rate [79], prediction of 
pCR without aggressive surgery is a research topic attracted broad interest in current 
clinical research field of breast cancer. Thus, identifying non-surgical or non-invasive 
imaging markers to predict pCR play important role to omit the unnecessary and 
aggressive surgery for the breast cancer patients with pCR to the neoadjuvant 
chemotherapy. 
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In this study, we developed and tested a new CAD scheme to investigate the 
association of MRI image features computed from the DCE-MRI scans performed after 
neoadjuvant chemotherapy in predicting the pCR of breast cancer. We demonstrated that 
using texture features along with the kinetic image feature computed from breast MRI 
after performing neoadjuvant chemotherapy carry useful information for predicting the 
pathologic response. It was shown in this study that fine gaussian support vector machine 
classifier can predict pCR with higher accuracy compared to other classifiers. To the best 
of our knowledge, the prediction of pCR for patients receiving neoadjuvant chemotherapy 
from the breast MR images using the fusion of kinetic and texture features has not yet 
been investigated.  
However, there are some limitations to our work. First, the number of the dataset 
is limited, and it is tried to perform our CAD scheme on a larger dataset to validate the 
performance of our CAD scheme. Second, different definition of pathological complete 
response should be added to investigate the different subtype of the tumors. In conclusion, 
we demonstrated that image features including kinetic and texture features extracted from 
breast MR images acquired after performing neoadjuvant chemotherapy can help in 
predicting pathological response to neoadjuvant chemotherapy. Finding of this study can 




Chapter 4: Implementation of a Computer-aided Detection Tool for 




Spontaneous, non-traumatic aneurysmal subarachnoid hemorrhage (aSAH) is most 
commonly due to ruptured cerebral aneurysm with an annual incidence of ~30,000 per 
annum in the US and affects middle-aged population with higher incidence among 
women and is associated with significant morbidity in survivors [80, 81]. This category 
of hemorrhagic stroke results in high individual and societal socioeconomic burden [82, 
83]. It is important for the clinicians to develop and implement an optimal personalized 
treatment and rehabilitation strategy for respective patients to help them recover quickly 
and also counsel families accurately regarding futility of care in patients with severe/near 
fatal aSAH. For this purpose, imaging plays an important role [84, 85] in current clinical 
practice. This calls for development of more effective radiological imaging based clinical 
markers that have higher discriminatory power to predict or assess prognosis of the stroke 
(aSAH) patients. However, due to the large number of images (CT or MRI), as well as 
the use of the subjective assessment methods, there are few quantitative studies in aSAH 
population [86, 87], which is not only labor-intensive (time-consuming), but also 
inconsistent due to the large inter-reader variability. 
In order to more accurately and quantitatively predict or assess the prognosis of 
aneurysmal subarachnoid hemorrhage patients, we developed and tested a new interactive 
CAD tool to automatically detect, segment and quantify two radiological image markers 
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namely, the volume and distribution of brain hemorrhage and ventricular cerebrospinal 
fluid regions depicting on brain CT images. The same interactive CAD schemes have 
been developed and tested in our previous studies for different types of medical images 
including mammograms [88 - 90], breast MRI [74], abdominal CT images [91]. In this 
study, our CAD scheme segments brain skull and assigns pixels into normal brain tissue, 
blood and fluid. To further increase accuracy in quantification of the image markers, we 
designed and implemented a graphic user interface (GUI) into the CAD scheme, which 
allows users to visually examine segmentation results and guide CAD scheme to 
automatically correct errors. Thus, unlike the qualitative features that were assessed and 
provided by the clinicians (e.g., radiologists) with established neuroradiological scales, 
namely Mod Rotterdam scale and Helsinki scale [92, 93], using our CAD enables to 
extract and compute quantitative image features. The overall goal of this study is to 
provide the clinicians a new computer-assisted tool to accurately and robustly measure 
these two clinical markers in the clinical settings using the brain CT images under 
potentially large variation of CT image characteristics and/or noise levels.  
Currently, this new interactive CAD has now been installed in the clinical and 
research settings in Department of Neurology, the University of Oklahoma Health 
Science Center (OUHSC) to conduct further clinical tests and studies. To report the study 
of developing this new interactive CAD scheme and results of testing the feasibility of 
using this interactive CAD scheme in our medical imaging laboratory and OUHSC 
clinical site, the organization of this Chapter is as follows: Section II and III describe the 
image dataset and the proposed CAD scheme applied over image datasets used in this 
study, respectively. Section IV summarizes our experimental results and Section V 
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discusses the observation and conclusions that we can make from our study results, 
respectively. 
 
4.2 Materials  
An image dataset of brain CT images including 96 patients who met the inclusion 
criteria was assembled. Each patient had the series images of axial view with image slides 
number between 30-60 slides. Of the 96 patients, 65 (68%) were female and 31 (32%) 
were male. In this dataset, mean and standard deviation of the patients’ age are 51.8±12.4 
and 51.2±13.2 for female and male, respectively, indicating that the majority of patients 
with brain hemorrhage were selected in this study are relatively older, i.e., >50 years old. 




We developed and tested a new CAD scheme to automatically segment brain tissue 
by removing brain skull and detecting brain hemorrhage and ventricular cerebrospinal 
fluid regions depicting on brain CT images. Once a case of brain CT examination is 
loaded into the program, an automated process steps are applied. There are five main 
image processing steps including: (1) applying region growing algorithm with adaptively 
adjusted threshold to remove brain skull and segment brain regions, (2) using 
thresholding algorithm to detect normal brain tissue, blood and fluid regions, (3) examine 
the segmentation result and applying the needed correction; and (4) computation of image 
features. The schematic overview of the entire segmentation workflow is presented in 
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Figure 11 and the details of each image processing steps are described in the following 
sections. Additionally, to avoid a “black-box” type approach and increase the confidence 
of the users to accept or consider CAD results, we also developed and implemented an 
easy-to-use graphic user interface (GUI), which make this CAD scheme an interactive 




Figure 11: Flow chart of subsequent steps of the brain segmentation 
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4.3.1. Brain region segmentation 
Brain region segmentation is an important step for the CAD scheme to automatically 
remove brain skull and segment brain tissue. Our CAD scheme first asks the user to create 
a seed point on brain tissue and apply the region growing algorithm to segment brain 
region and remove brain skull. Our CAD scheme uses a thresholding algorithm to 
differentiate regions from brain tissue and brain skull. 
 
4.3.2. Normal brain tissue, blood and fluid regions detection   
Second, in order to sign each pixel inside the segmented brain region into three 
categories or classes namely, normal brain tissue, blood and fluid, our CAD scheme 
applies a thresholding algorithm with two different values (TH1 > TH2) to detect desired 
regions. Since blood region is more enhanced in brain tissue, pixels with CT number 
above TH1 are segmented as blood region, while pixels with CT number less than TH2 
are segmented as fluid region. Pixels with CT number between TH1 and TH2 are 
classified as normal brain tissue. In the GUI window, the segmented normal brain tissue, 
blood and fluid regions are demonstrated in gray, light gray and black color, respectively. 
 
4.3.3 Segmentation examination and correction  
 
Although our CAD scheme enabled to achieve high accuracy in brain and ROI 
segmentation, errors do happen in a small fractional of image slices (e.g. ≤ 5 – 10%). In 
order to solve this practically operational issue and optimally compensate potential 
impact of CT image noise variation on different cases, users can visually examine 
segmentation results slice-by-slice to make sure that the segmentation results and the 
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correspondingly computed volumes of brain tissue, blood and fluid are satisfactory or 
acceptable. Figure 12 demonstrates an example of the process of our scheme 
segmentation. For this purpose, we designed and implemented a number of function 
buttons for the interactive correction which are listed below.  
 
1) Correction button – In the first step of brain region segmentation, if the segmentation 
has error (i.e., part of the brain is missing), the user can click a correction button, the 
scheme automatically corrects the error by mapping the new boundary condition 
based on the brain segmentation results in the adjacent CT slices.  
 
2) Removing false regions – CAD scheme has a function to allow the users convert the 
blood or fluid located in the irrelevant regions in to normal brain tissue region. An 
automatically converting process will be applied to the ROI created by the user. 
 
3) Morphological operations – This function button allows to perform morphological 
operations only inside the ROIs defined by the user to fill in the holes inside the blood 




Figure 12: An example of process of our CAD scheme. (a) Original image, (b) Skull 
removal and brain segmentation (c) Brain normal tissue, Blood and Fluid region 
detection which can be seen in gray, light gray and dark gray colors, respectively. (d) 
Removing false regions by creating a boundary around the ROI, (e) Final image ready 
for feature computation. 
 
4.3.4 Feature computation 
Finally, once the user satisfies with the results of each region segmentation, the 
CAD scheme computes total of 6 image features from the segmented regions, which are 
volume of total cranial, brain tissue, blood, fluid and ratio of blood volume over total 
cranial volume, and ratio of fluid volume over total cranial volume. These quantitative 




Under the IRB-approved data collection and study protocol, we have 
retrospectively acquired and assembled an initial testing image dataset involving pre-
contrast image series of 96 brain CT scanning cases in this study. Each case was of 
patients with non-traumatic aSAH of different clinical and radiological grades regarding 
to the disease severity. We applied our interactive CAD scheme to process dataset and to 
compute 6 image features as described above. Table 10 summaries minimum, maximum 
and average of the computed image features. The ratios range from 0.12% to 13.46% in 
this dataset, which indicates a big variation in the quantitatively assessed blood volumes 
among different patients in this dataset.  
 
 
Table 10: Summary of minimum, maximum and average of the quantitative image 
features. 
Features Minimum Maximum Average ± STD 
Brain Volume 958.62 1492.53 1156.2 
Blood Volume 0.92 94.92 18.11±18.29 
Ventricles Volume 5.52 91.63 27.67±16.28 
Tissue Volume 1079.58 1629.44 1296.29±139.03 
Ratio of Blood 
Volume over 
Brain Volume 
0.12% 13.46% 2.4%±2.57% 
Ratio of Blood 
Volume over 
Ventricles Volume 




Figure 13 shows an example of the interactive region segmentation steps and 
results. An original CT slice is displayed on the left. The image in the middle shows the 
result generated by the CAD scheme in the first automatic processing step, which shows 
the errors including missing a part of brain region (on the top) and detection of non or 
irrelevant blood ROIs or pixels due to the unavoidable CT image noise when using the 
regular threshold on CT number. After taking the interactive correction steps, the right 
image shows the final segmentation results in segmentation and quantification of brain 
region, as well as blood and fluid regions. The bottom part of the figure also shows the 
updated computation results.  
 
Figure 13: An example of brain segmentation using the correction tool to correct 
missing brain tissue area. Left image shows the original CT image, middle image is the 
segmented brain region missing one top bran tissue region and right image shows 
corrected image with both automatically and manually for all segmented regions. At the 
bottom of each image, 4 features were computed. Left column is related to total whole 
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series, middle column is related to middle image and right column is the features for 
corrected image. It can be seen by every changes value of computed features differ. 
 
We then analyzed the association between these features and the 
neuroradiological scales, namely Mod Rotterdam scale and Helsinki scale, commonly 
used in current clinical practice to assess severity and prognosis of stroke patients with 
aSAH. Table 11 and Figure 14 demonstrate the relationship or correlation coefficient 
between the computed image features (or segmented volumes) and the validated clinical 
evaluation indices (Mod Rotterdam and Helsinki sales). Among these relationships, ratio 
of blood volume over brain volume shows the highest correlation value with both Mod 
Rotterdam scale and Helsinki scale of 0.64 and 0.62, respectively.  
Specifically, the fit of the linear regression line equation for ratio of blood volume 
over brain volume and Mod Rotterdam scale was  
y = 0.0146x + 0.0032 
and the linear regression line equation for ratio of blood volume over brain volume and 
Helsinki scale was  
y = 0.0067x + 0.0006 
with R2 = 0.41 and R2 = 0.39, respectively. Therefore, for a computed ratio of the blood 
volume over brain volume of 0.04, Mod Rotterdam scale and Helsinki scale were 2 and 
4, respectively. 
 
Table 11: Correlation Coefficient between the computed image features and the clinical 
features. 
                                      Helsinki Scale 
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                                             Clinical Features                                           Mod Rotterdam 
Scale Computed Image Features 
Brain volume -0.04 -0.02 
Blood Volume 0.61 0.6 
Ventricles Volume -0.04 -0.02 
Tissue Volume 0.01 0.03 
Ratio of Blood Volume over Brain Volume 0.64 0.62 
Ratio of Ventricles Volume over Brain Volume -0.03 -0.02 
 
 
Figure 14. Scatter plots of ratio of blood volume over brain volume with Mod 
Rotterdam scale and Helsinki scale. Solid line is the linear regression line. 
 
4.5 Discussion 
Based on the imaging informatics concept, we in this study developed and 
demonstrated a new interactive CAD scheme/tool to help detect, segment and quantify 
brain volume, hemorrhage and CSF regions depicted on cranial area of brain CT images. 
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Our scheme cannot only automatically segment brain volume, the blood and CSF regions 
with a relatively high accuracy and computational efficiency, it also provides the unique 
interactive functions for the clinical researchers or users to conveniently examine and 
make correction (if necessary). This new ICAD scheme has been repeatedly tested by 
research assistants in our medical imaging (or CAD) laboratory. The testing results have 
been visually examined. Although CT image quality (signal-to-noise ratios) vary greatly 
among the brain CT image dataset, we found that using this interactive CAD scheme and 
GUI tool enabled users to adaptively process brain CT images and yield satisfactory 
results for the purpose of accurately and robustly segmenting and quantifying brain 
hemorrhage and ventricular cerebrospinal fluid depicting on the non-contrasted brain CT 
images. The preliminary feedback from the clinical researchers has also be encouraging, 
which indicated that using this new ICAD tool was much more user friendly and less 
cumbersome than other “black-box” type automated tools that have been previously 
tested for this type of studies to quantify various intracranial components or radiologic 
markers.  
 Thus, our study convinced our hypothesis that for this type of task aiming to 
accurately quantify two image based clinical or radiological markers using brain CT 
images of the stroke patients with spontaneous aSAH, accuracy and users’ confidence on 
the CAD-generated quantitative data is the most important if the such type of CAD 
scheme can be eventually accepted in the clinical practice to quantify image based 
markers to predict or assess prognosis of the aSAH patients. The interface of the 
interactive functions of our ICAD scheme have been modified or optimized based on the 
feedback of the clinical and research users. The scheme has now been installed in the 
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clinical and research settings and used by medical students or clinical researchers for 
conducting the related clinical studies to investigate several homeostatic derangements 
that occur after aSAH and correlate them with the clinical outcome. 
After installing this interactive CAD scheme and GUI tool in the Department of 
Neurology of OHHSC, the clinical researchers have used this ICAD scheme to evaluate 
the relationship between glycemic gap (GG) determined stress-induced hyperglycemia 
(SIH), modified Graeb score (mGS) and estimated intracranial blood and cerebrospinal 
fluid volumes, which have reported encouraging results in two papers recently published 
in two clinical oriented journals [94,95]. Specifically, volume of blood, CSF, and brain 
tissue (in ml) is estimated using this software program. Intracranial volume is determined 
as a combined volume of the above three parameters. Intracranial blood volume is 
expressed as a ratio of (blood volume to intracranial volume) × 1000. Such a ratio is used 
to obtain amount of intracranial bleeding in reference to respective individual’s 
intracranial volume. Similarly, total of blood volume and CSF estimates fluid volume and 
is expressed as (blood volume + CSF to intracranial volume) × 1000 to provide 
quantitative estimation of hydrocephalus.  
In the clinical study of OUHSC, the researchers retrospectively assembled a brain 
CT image dataset involving 187 patients over a 5-year period, which meet the inclusion 
criteria for the study. Among them, 38 patients (20.3%) expired during hospitalization, 
while 9 patients (4.8%) were discharged to an inpatient hospice facility. A GG of 26.7 
mg/dl was considered as the optimum threshold for SIH which resulted of ninety-four 
(50.3%) among the study cohort that had SIH. Baseline characteristics including patient 
demographics are enumerated in Table 12. 
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volume (in ml per 
1000 ml cranial 
cavity) 
Yes 39.6 33.6–45.5 
0.0002 
No 25.3 20.6-29.9 
Intracranial blood 
and CSF volume (in 
ml per 1000 ml 
cranial cavity) 
Yes 79.1 71.9-86.2 
0.027 
No 63.1 56.2-70.1 
Modified Graeb score 
Yes 4.0 2.0-7.0 0.002 
No 2.0 0.0–6.0 
 
Data analysis results indicated using this GG threshold, patients with SIH had 
14.3 ml/1000 ml more intracranial blood volume and higher mGS as compared to those 
without SIH [39.6 ml (95% confidence interval, CI, 33.6 to 45.5) vs. 25.3 ml (95% CI 
20.6 to 29.9), p = 0.0002] (Figure 15a, Table 12). Also, patients with third ventricular 
blood on admission CT scan were more likely to develop SIH [67/118 (56.8%) vs. 27/69 
(39.1%), p = 0.023].  
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Figure 15: Box plots show significant difference among patient developing stress-
induced hyperglycemia regarding to their respective intracranial hemorrhage volume (a) 
and degree of hydrocephalus (b) using quantitative estimation. 
 
Similarly, those with SIH had, on an average, 16/1000 ml of more intracranial 
blood + CSF volumes as compared to those without SIH [79.1 ml (95% CI 71.9 to 86.2) 
vs. 63.1 ml (95% CI 56.2 to 70.1), p = 0.027] (Fig. 15b; Table 12). Also, linear regression 
analyses showed strong relationship between volume of intracranial blood and 
intracranial blood + CSF with mGS. Hence, the present study, using unbiased SIH 
definition and objective CT scan parameters, reports “dose-dependent” radiological 
features resulting in SIH. Such findings allude to a brain injury-stress response-
neuroendocrine axis in etiopathogenesis of SIH. 
 
Based on our initial tests, our next short-term goal is to expand the retrospective 
database to include over 300 stroke patients with aSAH. We are now planning to apply 
this new ICAD scheme to process all of these cases and compute the cerebral hemorrhage 
and/or ventricular cerebrospinal fluid related image (clinical or radiologic) markers. The 
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detailed statistical data analysis study to assess the association between these image-based 
markers and prognosis of the aSAH patients will follow. Although reporting the 
comprehensive data analysis of this database of over 300 aSAH patients is beyond the 
scope of this technology development study, this technology development based study is 
an important step and successfully demonstrated its feasibility or clinical utility in order 
to make the contribution of helping clinicians more effectively conduct quantitative 








Immunohistochemistry (IHC) is an important and commonly used method for 
cancer diagnosis in pathology, which is used to visualize certain antigen (protein) as the 
target in cellular (tissue) samples using monoclonal or polyclonal antibodies. In most 
cases, the antibody is conjugated to an enzyme, which catalyzes a color-produced reaction 
that enables the detection of the antigen. Alternatively, the antibody can be conjugated to 
a fluorochrome to detect the presence or absence of the marker.  
 
Thus, identifying the right antibody that can conjugate specifically to the targeted 
disease is the most important task in the whole IHC assay development process. To 
achieve this, a large amount of antibodies need to be screened, which is conventionally 
performed by pathologists through manual slides reviewing. Usually, slides stained by 
3,3´-Diaminobenzidine (DAB) with hemotoxylin (HTX) counter stain are used, where 
the presence of specific DAB stain indicates the desired reaction of the antibody. It is 
known that 30%~50% of the antibodies under screening can be non-reactive to the target, 
resulting in slides with little DAB stain (i.e, negative slide).   
 
The purpose of this study is to develop a new CAD scheme to automatically identify 
the non-negative slides and thus reduce the pathologists’ manual reading time, which 
aims to eventually improve the efficiency of antibody development. We focused on using 
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both low and high resolution digital pathology images to extract image features in a two-
step scheme to optimize algorithm efficiency and accuracy, especially for the challenging 
cases where the desired specific DAB stain was very weak or sparse on the slide. We also 
experimented with different machine learning algorithms, including hand-crafted and 
convolutional neural network (CNN) based feature extractions.  In addition, the algorithm 
was integrated to a web-based image management platform to facilitate easy deployment 
to the clinical users.  
 
5.2 Materials  
Two digital pathology image datasets with 285 and 279 slides were 
retrospectively assembled as training and testing dataset, respectively. Each dataset was 
divided into two groups namely, negative vs. non-negative groups. The negative group 
included images with little DAB stain and non-negative group included images with 
partial or pure background DAB stain. The training dataset included 126 negative and 
159 non-negative slides, while the testing dataset included 130 negative and 149 non-
negative slides, respectively. Figure 16 demonstrates several sections of the images 
namely, the field-of-view (FOV) examples of negative and non-negative slides, which 
shows that the problem is not trivial, as DAB stain can present in negative slide (Fig.16 







Figure 16: Examples of FOV images (a-c) from negative and (d-f) non-negative slide. 
 
5.3 Methods 
In the study, our CAD scheme first applied color deconvolution to the low 
resolution whole slide image and extracted histogram based image features. The color 
deconvolution method developed by Nie et al [96] was used to unmix the digital 
pathology image into single stain images. As the result, three new images (i.e., HTX, 
DAB and total Absorbance of all the stains) were generated, which were used for feature 
computation. Different machine learning algorithms including linear supported vector 
machine, (LSVM), k-nearest neighbors (KNN) were built using the training dataset 
through a ten-fold validation method. Next, as the initial classification process, the trained 
models were tested over the testing dataset. The classification results showed that LSVM 
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achieved the highest area under ROC curve (AUROC). Therefore, we used the LSVM 
score to derive the cutoff points for identifying slides that need further analysis. The 
lower- and upper-cutoff points were defined such that there were no misclassified slides 
from the training dataset with a LSVM score that is lower(higher) than the lower(upper)-
cutoff points.  
In the next step, whole slide images that needed further analysis were divided into 
non-overlapping tiles at high resolution. Color deconvolution was applied to each tile and 
more sophisticated image features were extracted. We experimented with histogram 
based features, as well as features derived from the intermediate layers of pre-trained 
convolutional neural network (CNN), such as AlexNet. Based on these extracted features, 
whole slide image representation was derived utilizing a Bag-of-Words (BoW) model. 
Specifically, image tiles from the training dataset were clustered into a predefined number 
of clusters; and the centers of the clusters collectively form a visual words vocabulary. 
For each tile in a whole slide image, a visual word was assigned by identifying the cluster 
that the tile belongs to. Thus, each whole slide image can be represented by the histogram 
of the occurrence of each visual word in the vocabulary.  Finally, the second classifier is 
trained using the BoW whole slide image representation to perform the negative vs. non-
negative prediction. The schematic overview of the entire classification workflow is 
























Figure 18 shows several example results of applying the color deconvolution 
method on the low resolution whole slide image.  
 
Figure 18: The graphical user interface developed for showing color deconvolution 
results. a) low resolution negative image, b) HTX generated from the negative image, c) 
DAB generated from the negative image, d) low resolution non-negative image, e) HTX 
generated from the non-negative image and f) DAB generated from the non-negative 
image. 
 
For the initial classification, different machine learning algorithms were applied 
to build prediction or classification models using the training dataset. The trained models 
were then tested by the independent testing dataset. Table 13 shows a list of machine 
learning classifiers and their performance on the testing dataset. Among them, linear 
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SVM shows higher accuracy of 82% with AUROC of 0.86. The sensitivity and specificity 
of the linear SVM were 80% and 84%, respectively.  
 
Table 13: Comparison of prediction performance using different machine learning 
models. 
Machine Learning Model Accuracy Sensitivity Specificity 
Linear SVM 82% 80% 84% 
Fine Tree 70% 68% 72% 
Fine KNN (K=1) 75% 74%     76% 
Medium KNN (K=10) 75% 68% 85% 
RusBoosted Tree 68% 65% 70% 
Boosted Tree 57% 55% 57% 
 
Figure 19 shows the histogram plot of the initial classification result using linear SVM 
model for the negative and non-negative slides of the training dataset. Results indicated 
that the cutoff points are -1.5 and 2.75 for negative and non-negative slide, respectively. 
Any slide with a linear SVM score between the two cutoff points was identified as a slide 




Figure 19: The histogram plot of the linear SVM scores in the initial classification. 
Negative and non-negative slides are shown as blue and orange, respectively. 
 
From the training dataset out of 285 cases, and from testing dataset out of 279 cases, 
244 and 218 cases were between the two cutoff points, respectively. In our scheme, a total 
of 180 tiles of 500x500 pixels were generated from each high resolution whole image to 
apply the final classification. The tile selection was performed by first computing the 
mean DAB intensity value of each tile. Then, different percentiles of the mean DAB 
intensity values were calculated such that half of which were evenly distributed between 
the 80th~99th percentiles, and others were evenly distributed between the 20th~80th 
percentiles. For each selected percentile, a same number of tiles with mean DAB intensity 
value closest to the percentile were selected, resulting in the final 180 tiles to represent 
the whole slide image, and the majority of which had relatively high mean DAB 
intensities. The rationale behind this tile selection approach is based on the assumption 
that tiles with relatively higher mean DAB intensity values in each slide are more relevant 
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for differentiating negative vs. non-negative slides, which was found true though our 
experiments.  
The stain intensity histogram based features and features derived from the 
intermediate layer of the pre-trained AlexNet network were extracted for each tile to 
derive the BoW representation for the whole slide image. Different number of clusters 
including 30, 35, 40, 45 and 50 were tested to evaluate the prediction performance. Using 
the training dataset, 21 different machine learning classifiers were built, trained and tested 
over testing dataset, including Fine K-Nearest Neighbor (KNN), Medium KNN, Coarse 
KNN, Cosine KNN, Cubic KNN, Weight KNN, Linear SVM, Quadratic SVM, Cubic 
SVM, Fine Gaussian SVM, Medium Gaussian SVM, Coarse Gaussian SVM, Ensemble 
Boosted Tree, Ensemble Rusboosted Tree, Fine Tree, Medium Tree, Coarse Tree, 
Ensemble Subspace Discriminant, Ensemble Subspace, Ensemble Bagged Tree and 
Linear Discriminant. Table 14 and 15 show a performance comparison of different 
number of clusters using the trained models using the histogram-based features and neural 
network generated features, respectively. For each cluster number, the results for the best 
classifier with accuracy value above 70% are reported. 
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Table 14: Comparison of the best classification performance using different number of 
clusters over histogram based features. 
Machine Learning Model - # of 
clusters 
Accuracy Sensitivity Specificity 
EBGT* - 30 74% 83% 66% 
CGSVM** - 35 76% 88% 66% 
EBGT - 40 80% 85% 74% 
CGSVM - 45 77% 91% 67% 




Table 15: Comparison of the best classification performance using different number of 
clusters over neural network based features. 
Machine Learning Model - # of 
clusters 
Accuracy Sensitivity Specificity 
Ensemble Subspace Dis - 30 81% 84% 77% 
Ensemble Rusboosted Tree - 35 84% 80% 89% 
EBGT- 40 83% 91% 73% 
Ensemble Subspace Dis - 50 81% 82% 79% 
 
Results from Table 14 indicate that although using Ensemble Bagged Tree (EBGT) 
classifier with number of clusters of 40 achieved higher accuracy, using Coarse Gaussian 
SVM (CGSVM) classifier yielded the highest sensitivity of 91% and AUROC curve 
value of 0.88. While EBGT showed better accuracy for using the histogram-based 
features, Ensemble Rusboosted Tree classifier showed better performance for using 
neural network generated features. Also using EBGT classifier for neural network 
generated features achieved overall highest performance in accuracy, sensitivity and 
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AUROC with the value of 83% and 91% and 0.91, respectively. It is worth mentioning 
that, superior sensitivity is preferred for this particular application, because non-negative 
slides identified by the CAD scheme will be sent to pathologist for further review. Thus, 
including a small number of misclassified negative slides is more acceptable than missing 
non-negative slides that may contain important information regarding reactive antibodies.  
 
5.5 Discussion 
Primary antibody development for IHC assay is to identify the antibody that is 
conjugated specifically to the target antigen. For this purpose, the first question to answer 
is whether the antibody under study is conjugated to the tissue in general regardless of 
the staining specificity, which is the problem addressed in this study. In comparison to 
the widely known IHC scoring applications for clinical diagnosis, such as Ki67 and 
human epidermal growth factor receptor 2 (Her2), etc., where a quantified score needs to 
be derived through calculating the percentage of positively stained tumor cells, our study 
and CAD scheme focus on differentiating reactive vs. non-reactive antibodies at whole 
slide level. Therefore, our focus is naturally formulated as a binary classification problem 
namely, differentiating non-negative vs. negative slide. Under such formulation, the 
ground truth available to us is the whole slide level labels, which lead to our strategy of 
employing slide and tile level image features to derive the whole slide representation for 
building the classification model. Cell level image features, although potentially more 
descriptive in local regions, are not considered in this explorative work due to the fact 
that cell level ground truth is not well defined for this general application. The experiment 
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results demonstrated that the proposed CAD scheme achieved encouraging results 
without the need of computationally expensive cell level analysis.  
On the other hand, tile selection seems to play an important role in the proposed 
scheme. In fact, we examined the scheme using all the tiles from each whole slide image, 
which showed inferior performance in classifying the slides comparing to using only 180 
tiles. This could be due to the fact that using all the tiles from a whole slide image results 
in employing too many tiles with sparse DAB stains in non-negative slide, which often 
have similar appearances as the tiles in negative slides.  Using presented tile selection 
criteria in this study, better classification performance was achieved, which confirmed 
our assumption that tiles with relatively higher DAB intensity level were more 
representative for identifying reactive vs. non-reactive antibodies through whole slide 
assessment.  
However, despite the encouraging results, this is a preliminary study with several 
limitations. First, this study used a small image dataset which may not sufficiently 
represent the image diversity in this application. Second, by finding that using all the tiles 
in the whole may not be the optimal approach. Thus, there exits great room for future 
investigation on tiles selection to derive a better representation of the whole slide. 
Moreover, CNN based features were explored as is, more research work is needed to 
design a training scheme that enables fine tuning the network parameters to further 
improve the performance for this particular application. Our next step includes 
investigating the non-negative slide and automatically excluding pure background 
staining cases, which will further reduce the manual reviewing time by pathologists.  
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Chapter 6: Developing a CAD-based Slide Label Reader to Improve 
Efficacy of Storing Digital Pathology Images 
6.1. Background 
The pathology discipline has its basis in over 150 years old tradition of using 
microscopes to review and diagnose tissue samples. Tissue samples are collected by 
surgeons or other clinicians and sent to the pathology laboratory for analysis. The largest 
hospital in each county is equipped with a pathology laboratory that receives tissue 
specimens or bodily fluid from other departments or hospitals. The technicians in 
pathology laboratory processes the material and creates glass slides with pieces of the 
specimens and finally, a pathologist reviews the content on the glass slide and dictates a 
report that is sent back to the referring physician. 
The typical tissue specimens arrive at the pathology laboratory in a plastic box 
filled with formalin. A pathologist or laboratory technician performs a grossing 
examination of the specimen. This examination consists of measuring, sketching, and 
sometimes taking photos of the specimen. Small pieces of tissue are cut out for further 
analysis, see Figure 20(up left). These pieces are further processed in a sequence of 
chemical solutions by an automatic processing machine and then embedded into paraffin 
blocks (Fig. 20 up right). From these paraffin blocks, small sections of tissue are sliced 
using a microtome. The microtome enables to create micrometer thin sections, which are 
placed on warm glass slides where it will be immediately fixed (Fig. 20 down left). At 
this stage, the resulting sections are almost transparent. In order to reveal the tissue 
structures, the glass slides are stained with different colors that attach to different types 
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of structures. For each specimen, this process can result in a large set of glass slides (Fig. 
20 down right).  
 
Figure 20. The process of producing glass slides. (up left) Small pieces of tissue are 
selected for processing. (up right) Pieces of tissue embedded in paraffin block. (down 
left) Paraffin block are cut with a cryostat microtome and being prepared for staining. 
(down right) Tray of glass slides ready for review. 
 
Finally, the pathologist reviews the content of the glass slides with a microscope 
and dictates a report. This work is typically organized as a sequential production line in 
multiple steps, consisting of different kinds of processing and selection steps as in Figure 
21. If the patient has given written consent, the glass slides and the embedded blocks are 




Currently, in the pathology laboratory in USA, more than 50,000 glass slides 
(range of 14,000 to 100,000 cases/specimens) are being stained per year and the scale is 
increasing. Since slides are glass based, it is very easy to get damaged and break and 
storing and archiving is not an easy task (Figure 22). Also, the information regards each 
slide is paper based and slides are reviewed manually by the microscope.  
 
Manual data entry is currently a bottle neck in the laboratory operations and 
carries the risk of data damage, loss and error. Besides the time consuming process, prone 
to errors, subject to human resource fluctuations and expensive to scale are the limitations 
of using manual data entry. Different approaches such as training the employees with the 
importance of the data and using software tool can reduce manual data entry errors. 
Figure 21. The histopathology laboratory workflow. 
Figure 22. Storing glass slide is not an easy task. 
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Currently, using software tools to import data into computer systems is playing an 
important rule to help the archiving and tracking the information from each glass slide. 
 In the pathology laboratory, every tissue glass slide has labels which have been 





Each label has meta data information related to that glass slide. Clone name, 
development, target name, detection method, tissue type, staining date, dilution factor, 
immunogen, AR field, autostainer and slide numbers are a number of metadata being 
mentioned on the slide label. Each glass slide with the label is scanned with the iScanHT 
scanner machine. Figure 24 demonstrates two examples of tissue glass slides with two 
different slide label platform.  
Figure 23. Two example of staining machines used in pathology laboratories. 




Figure 24. Two examples of glass slide tissues with different labels platform. Ultra 
label (left) and autostainer label (right). 
  
In order to reduce the manual work for slide tracking and archiving in the 
pathology laboratory and transferring all hard copy into a digital copy, a software tool 
with graphical user interface is designed to automatically extract metadata from tissue 
slide label images and store the information in the archive in digital form. 
 
6.1.2. Methodology 
Two types of tissue slides stained by Ultra and Autostainer platforms were 
scanned by iScanHT scanner and the label images are automatically extracted. Figure 25 
demonstrates the interface window and the description of a different section of this 




Figure 25. Graphical user interface window. 
 
I. Generate Label 
iScanHT scanner will scan the microscope slide and save the file as a tiff file which 
includes both tissue and label part of the glass slide. In order to process the labels, a 
generating algorithm is applied to create a .png file and extract the labels from the glass 
slide. By selecting the “Generate Label” the program asks the user to select the folder that 
contains different projects and start generating labels. A simple algorithm is used to select 
the labels region on the glass slide and save the ROI as a .png file. Since the workplace 
that we designed this software for is using a shared drive, loading and saving files from 
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the shared drive is taking a long time. With this key, user is able to put the program to 
work overnight and generate all the labels at one time. 
II. Process  
Different challenges with labels quality were faced during meta data information 
extraction process. Examples of challenges including, rotation of the label, stain leaked 
over the text part, scratch on the text part are shown in Figure 26. 
        
Figure 26. Examples of the challenges with labels. Rotation, scratch on text part 
and stain over text. 
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Due to requests of the pathologist and challenges with the labels, different processing 
algorithms are designed to extract meta data information. Processing algorithms include: 
1) individual process to be applied over labels individually and extract information one 
by one, 2) batch process to be applied over all the labels and extract information for all at 
once, 3) batch process with the library to be applied over a selection of the labels with 
having a set of similar meta information, and 4) is the easy mode which is only reading 
the information which is not similar among labels. The details of each process are being 
described in the following sections. 
a)  Individual Process 
As mentioned before, the individual process is processing each label individually and 
one by one. By pressing the “Load Label”, user is able to select the desired project folder 
containing labels and start the process. First, the program used a neural network based 
image classification algorithm to identify the label type and decide to choose the ultra or 
autostainer methods for extracting meta data information. Next, a set of pre image 
processing algorithms were applied to generate a better quality of the image and prepare 
image for text reading. Afterward our trained optical character recognition algorithm was 
applied to identify the texts in each label image. Based on the label type, each text will 
be assigned to a specific item for meta data information and the results will be shown in 
the information panel. Pressing the “Next” key allow users to go through each label 
individually and process the result one by one. Although using this process is time 
consuming but the accuracy of the result is high since the user is able to go through each 
label and check the result. Finally, the “Save” key allows users to export and save their 
extracted metadata into a csv file. This csv file later is used for uploading into a digital 
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pathology platform where the tissue slide images were hosted. Figure 27 shows the keys 
for individual process. 
 
Figure 27. Individual process panel 
b)  Batch Process 
      This key processes all the images of a project at the same time and the results 
will be saved automatically into a csv file. By pressing the “Batch process” key, the 
interface ask user to select a folder to contain the labels and start processing all the labels 
at the same time. The process steps are similar to individual process, starting with a neural 
network to identify label type, using a set of –pre image processing to increase the label 
quality and then applying optical character recognition algorithms to extract text and 
assign each text item to a specific meta data information. The end of the process will be 
shown with a message box of “Operation Completed”. Using batch process is much more 
efficient than individual process due to taking less time than individual process and 
availability to work overnight.  
c) Batch process with library 
     In pathology labs, in the process of generating slide tissues, there will be glass 
slides with similar information such as tissue and target. The batch process with the 
library process is designed based on projects that have similar tissue or target information. 
The process is similar to batch processing with an additional step. By pressing the batch 
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process with a library key, a new window (library selection, Figure 28) is shown to the 
user to select the desired target and tissue. Pathologists prepared a list of the most 
common target and tissue items and these lists are stored in the program library. When 
user choose “Target” or “Tissue” key, the library related to it will be loaded to program 
and ask users what target or tissue name is desired (Figure 29).  
 
 












































User is allowed to select as many target or tissue desired. This process helps the 
program to have a reference for target and tissue information and if there is scratch or 
stain over text, program is able to retrieve the information based on the references selected 
by the user from the library. As an example, Figure 30 demonstrates a label with 
difficulties in reading the tissue information. Due to the difficulties in reading the 
information, optical character recognition is not able to extract the correct information 
from the image for tissue information. Using the tissue library and selecting some 
references, program gives a score to the possibilities of each selected library. The 
reference with the highest score will be selected as the final result. The correct answer for 
tissue information for figure 10 is 158261_PL, the first result from OCR will be 
158261_PI. If user select different references such as “PL”, “PLC” as tissue library, 
program will give scores to each reference based on the similarity with the result of the 
OCR. Since OCR got the tissue as “PI”, the reference of PL will receive higher scores 
more than “PLC” and the program will give “158261_PL” as the final result. 
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Figure 30. Example of missing text on label resulting difficulties in generating correct 
information. 
d) Easy mode 
      Due to the requests of the pathologist, “Easy mode” process was designed to 
make the progress faster. For this process, user is having a specific project containing 
different labels with similar information in different sections and only one meta data is 
different. As an example, there will be projects defined to have similar label types, 
development, detection method, target, tissue, stain date, dilution facto and immunogen 
and only clone name is different. With this information entered into the program, program 
will read only the information that is not given and less time will be put over processing. 
By selecting the “Easy mode”, the name selection window will show up and allow user 
to decide what are the similarities among the labels. Pathologists provided a list of all 
common meta data information for each item which can be updated in the future. By 
selecting each key from “Select Information” panel, a list of all available information will 
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be shown and allow user to select one item which is going to be similar among all labels. 




Figure 31. By pressing “Easy mode” key, a window with “select formation” panel will 




III. Quality Control: 
In order to allow user to easily check the result of the interface and the extraction 
of the meta data, a quality control section is added to the program. This panel allows user 
to visually see the label processed and show the result of each meta data. Figure 32 
demonstrates the quality control panel with the keys implemented. “Load” key will load 
all the labels in a project and the slide bar allow user to go through each label and enter 
any correction needed in the main information panel. In the end, user is able to save the 
updated information and update the previously generated csv file. 
 
 
Figure 32. Quality control panel with the keys and slide bar. 
 
6.1.3 Conclusion 
This tool was tested over 277 tissue slide labels with different challenges 
including label damage, rotation, stain over texts, etc. Label type identification achieved 
100% accuracy and all labels correctly identified as Ultra or Autostainer label. The 
individual screening method took one hour as the user visually examined the results 
during the process through the tool’s user interface and received the higher accuracy. 
Batch Processing is more efficient since it only took one minute to process the dataset 
with an error rate of 15%. Further improvement can be achieved by developing a 
dedicated quality control interface used at the end of batch processing.   
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Chapter 7: Conclusion and Future Work 
7.1 Summary 
To improve efficacy of disease diagnosis and treatment, a recent precision 
medicine initiative calls for developing a new disease treatment strategy that takes 
individual variability into account [97]. In response to this initiative, the researchers in 
medical imaging informatics field hypothesized that developing and applying computer-
aided detection and diagnosis (CAD) schemes can play an important and unique role to 
help establish the new precision or personalized medicine paradigm. Besides the 
conventional CAD schemes that focus on detecting suspicious lesions and serve as “a 
second reader” to help radiologists detect more cancers in cancer screening environment, 
new and novel CAD schemes have been developed in recent years, which have 
demonstrated their capability and advantages to much broad clinical applications, such as 
predicting short-term risk of cancer development, classifying between malignant and 
benign lesions, determining disease severity and types, predicting disease prognosis, 
assessing efficacy of treatment and clinical outcome (i.e., disease-free or progression-free 
survival).  
 In the previous chapters of this dissertation, I present and report several new CAD 
schemes, which were developed and evaluated in my PhD studies. In Chapters 2 and 3 I 
present and discuss new CAD schemes of breast MRI acquired pre- and post-neoadjuvant 
chemotherapy of breast cancer patients to predict radiographic complete response and 
pathologic complete response of breast cancer patients to the therapies. In Chapter 4 I 
present and discuss a new interactive CAD scheme to detect, segment and quantify 
severity of aneurysmal subarachnoid hemorrhage (aSAH) of stroke patients using brain 
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CT images.  In Chapter 5 I present and discuss another CAD schemes of digital pathology 
images using both histogram-based features computed from low resolution images and 
convolution neural network (CNN) generated features computed from the high resolution 
images to identify the ROIs in which tissues or cells are responsive to the specific 
antibody stains. In Chapter 6 I present and discuss a unique and efficient CAD scheme 
with optical character recognition algorithm to identify the label type between ultra and 
autostainer of pathology images to facilitate the efficiency of digital pathology image 
storage. 
The effort and contribution of my PhD research work include (1) developing and 
testing new image processing algorithms to segment regions of interest (i.e., breast areas 
in MRI, blood or aSAH regions in brain CT images, and antibody-responsive regions or 
cells in digital pathology images), (2) selecting optimal image features from the initially 
large feature pool, (3) training and cross-validating machine learning models or classifiers 
to minimize bias and overfitting, and (4) developing and implementing interactive CAD 
schemes with easy-to-use graphic user interface to increase the flexibility of the using 
CAD scheme and confidence of the clinicians to accept CAD-generated results. Through 
these studies, we published following papers in which I am a co-author during the period 
of my PhD studies. 
A. Journal Papers 
1. Aghaei F, Tan M, Hollingsworth AB, Qian W, Liu H, Zheng B, Computer-aided 
breast MR image feature analysis for prediction of tumor response to 
chemotherapy, Medical Physics 2015; 42:6520-6528. 
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2. Aghaei F, Tan M, Hollingsworth AB, Zheng B, Applying a new quantitative 
global breast MRI feature analysis scheme to assess tumor response to 
chemotherapy, Journal of Magnetic Resonance Imaging, 2016; 44:1099-1106. 
3. Tan M, Aghaei F, Wang Y, Zheng B, Developing a new case based computer-
aided detection scheme and an adaptive cueing method to improve performance 
in detecting mammographic lesions, Physics in Medicine and Biology 2017; 
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7. Danala G, Patel B, Aghaei F, Heidari M, Li J, Wu T, Zheng B, Classification of 
breast masses using a computer-aided diagnosis scheme of contrast enhanced 
digital mammograms, Annals of Biomedical Engineering, 2018; 46:1419-1431. 
8. Santucci J, Ross S, Greemert J, Aghaei F, Ford L, Hollabaugh K, Conwell B, Wu 
D, Zheng B, Bohnstedt B, Ray B, Radiological estimation of intracranial blood 
volume and occurrence of hydrocephalus determines stress-induced 
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Research 2019; 10:327-337. 
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B. Conference Proceeding Papers 
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breast MR image feature analysis for prediction of tumor response to 
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3. Tan M, Aghaei F, Hollingsworth AB, Stough RG, Liu H, Zheng B, Increasing 
cancer detection yield of breast MRI using a new CAD scheme of mammograms, 
Proc SPIE 2016; 97850R. 
4. Gaffney KP, Aghaei F, Battiste J, Zheng B, Automated detection and 
quantification of residual brain tumor using an interactive computer-aided 
detection scheme, Proc SPIE 2017; 101342I. 
5. Aghaei F, Mirniaharikandehei S, Hollingsworth AB, Wang Y, Qiu Y, Liu H, 
Zheng B, Exploring a new bilateral focal density asymmetry based image marker 
to predict breast cancer risk, Proc SPIE 2017; 101361P. 
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classification of breast masses using contras-enhanced digital mammograms, 
Proc SPIE 2018; 105752K. 
11. Aghaei F, Danala G, Wang Y, Zarafshani A, Qian W, Liu H, Zheng B, 
Association between mammogram density and background parenchymal 
enhancement of breast MRI, Proc SPIE 2018; 105752O. 
12. Mirniaharikandehei S, Zarafshani A, Heidari M, Wang Y, Aghaei F, Zheng B, 
Applying a CAD-generated imaging marker to assess short-term breast cancer 
risk, Proc SPIE 2018; 105753F. 
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13. Aghaei F, Danala G, Hollingsworth AB, Stoug RG, Pearce M, Liu H, Zheng B, 
Applying a new mammographic imaging marker to predict breast cancer risk, 
Proc SPIE 2018; 105753N. 
14. Aghaei F, Mirniaharikandehei S, Hollingsworth AB, Stoug RG, Pearce M, Liu 
H, Zheng B, Association between background parenchymal enhancement of 
breast MRI and BIRADS rating change in the subsequent screening, Proc SPIE 
2018; 105790R. 
15. Aghaei F, Hollingsworth AB, Mirniaharikandehei S, Wang Y, Liu H, Zheng B, 
Developing a new quantitative imaging marker to predict pathological complete 
response to neoadjuvant chemotherapy, Proc SPIE 2019; 109502O. 
16. Zarafshani A, Wang Y, Mirniaharikandehei S, Heidari M, Aghaei F, Wang S, 
Xiang L, Zheng B, Design, fabrication and evaluation of non-imaging, label-free 
pre-screening tool using quantified bio-electrical tissue profile, Proc SPIE 2019; 
1095304. 
17. Danala G, Heidari M, Aghaei F, Ray B, Zheng B, Developing a computer-aided 
image analysis and visualization tool to predict region-specific brain tissue “at 
risk” for developing acute ischemic stroke, Proc SPIE 2019; 109530M. 
18. Aghaei F, Nie Y, Computer Aided Antibody Screening for IHC Assay 
Development, Proc SPIE 2019; 109560C.  
In summary, besides the publications, the most significance or contribution of my 
research work is that several CAD schemes and GUI tools discussed in this dissertation 
have been implemented and used by the clinical researchers in OUHSC and biomedical 
engineering researchers in Roche company. The promising study or test results have been 
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reported in these independent studies. Thus, my research work demonstrates the 
feasibility of developing and applying new novel CAD schemes to extract quantitative 
image markers and build machine learning models for variety of medical image based 
disease detection, diagnosis and prognosis assessment. The interactive CAD schemes 
with GUI can provide clinicians the decision-making support tools to help them more 
accurately diagnosis diseases and make optimal treatment decisions for the patients. 
 
 
7.2 Future works  
 
Although great research efforts have been made in developing and testing new 
CAD schemes for many different clinical application purposes, many technical 
challenges remain to develop the CAD schemes with high scientific rigor (or robustness) 
due to several factors, which include (1) difficulty and errors in segmentation of disease 
or other related regions of interest, (2) potential bias in feature computation and selection, 
(3) the limited size of image datasets to train and cross-validate machine learning models, 
and (4) the gap between computer vision and human vision. Thus, many development 
and optimization issues still need to be better investigated and solved before any CAD 
schemes can be optimally implemented and used by the clinicians in the clinical practice. 
Based on the knowledge and hand-on experience that I have leant from my previous 
studies, I will continue investigating these issues and exploring novel approaches trying 
to make new progress or contribution to help solve these issues in my future work.  
For example, I will continue focus on developing and implementing new CAD 
schemes of digital pathology images. Every year, an average of approximately 50,000 
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cytology specimens are produced.. Pathology images can be equal to information sent 
from a satellite in space over street map regard size which means much information exists 
in one whole slide digital pathology image. The combination of image analysis and 
machine learning over digital pathology images can be used to automatically segment 
cells and detect normal and tumor cells. The research scientist and pathologist will 
continue to be instrumental in both the use and operation of image analysis workflows, 
which will continue to evolve preclinical and clinical biomarker research. Also, taking 
advantage of new research topics such as deep learning on pathology images can help in 
improving the detection and analysis of digital pathology images. In conclusion, my next 
short-term goal is to work on detection and segmentation of tumor cells depicted in digital 
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